Background: A single nucleotide polymorphism (SNP) in the tyrosine phosphatase gene PTPN22 (R620W) and smoking have been shown in epidemiological studies to interact to confer an increased risk of RA. The molecular basis for this interaction is unknown but PTPN22/Lyp regulates signalling through immune cell receptors. Lyp is expressed in T lymphocytes, which are important in adaptive immunity, but aberrant T-cell receptor (TCR) signalling may promote autoimmunity. Here we investigated how PTPN22 R620W and smoking effect Lyp activity, TCR signalling and function, to determine possible mechanisms by which the allelic variant could interact with smoking to promote disease. Methods: A cohort of healthy controls (n ¼ 62) were genotyped for the PTPN22 R620W SNP. CD4þ T cells were isolated from control (GG) and heterozygous/variant (AG) subjects and exposed to cigarette smoke extract (CSE). The phosphatase activity of Lyp and phosphorylation status of the Lyp substrate Lck were assessed. The effects downstream from Lyp were determined by measurement of proliferation and cytokine production. Results: The R620W allele (A) was highly expressed in healthy controls (AG ¼ 28%, AA ¼ 1%, GG ¼ 71%), and 17 heterozygous/variant individuals were identified. The amount of Lyp protein was significantly decreased in variant T cells (GG ¼ 1.2 ng AE 0.3/1.0 x 10 6 cells, AG ¼ 0.7 ng AE 0.1/1.0 x10 6 cells, P < 0.05, n ¼ 8), but there was no significant difference in phosphatase activity. The decreased amount of Lyp variant protein had a higher specific activity resulting in no overall change in Lyp activity. There was no difference in phosphorylation of the Lyp substrate Lck on tyrosines 394 or 505. Proliferation of control and variant T cells was equivalent, and unaffected by CSE. Cytokine profiles were significantly different, with variant Lyp T cells producing more IFN (GG ¼ 221 pg/ml AE 60, AG ¼ 400 pg/ml AE 64, P < 0.0005, n ¼ 4) and TNFa (GG ¼ 237 pg/ml AE 26, AG ¼ 308 pg/ ml AE 9, P < 0.05, n ¼ 4) compared with controls. Production of TNFa was decreased by CSE treatment in both cell types, with variant Lyp T cells being more sensitive to CSE. Low concentrations of CSE had no effect on IFN production by variant T cells; however control T cells increased secretion, and thus produced comparable amounts of IFN to variant T cells (GG ¼ 312 pg/ml AE 77, AG ¼ 340 pg/ml AE 46, n ¼ 4). Secretion of IL-4, IL-10 and IL-17 were not significantly different in control and variant T cells, or following CSE treatment. Conclusions: The PTPN22 R620W allelic variant was common in the cohort tested, and its expression results in decreased Lyp protein, but increased phosphatase activity in CD4þ T cells. Although phosphorylation of the Lyp substrate Lck was unchanged, the PTPN22 R620W variant resulted in increased production of inflammatory cytokines. This also occurred after exposure to CSE, suggesting R620W and smoke may synergise to promote inflammatory T cells. Disclosures: The authors have declared no conflicts of interest.
ALTERED FREQUENCIES OF REGULATORY T-CELL SUBSETS IN ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS PATIENTS AND THEIR RESPONSE TO ANTI-TNF THERAPY
Moreover, in both AS and RA patients, the frequencies of effector and naïve Treg were decreased (effector Treg: NC ¼ 0.73% AE 0.07%, AS ¼ 0.48% AE 0.07%, P < 0.05, RA ¼ 0.34% AE 0.06%, P < 0.001; naïve Treg: NC ¼ 2.18% AE 0.33%, AS ¼ 1.10% AE 0.15%, P < 0.01, RA ¼ 1.00% AE 0.15%, P < 0.01;). Anti-TNF therapy increased the frequency of both naïve and effector Treg in AS patients, whilst in RA patients only the frequency of effector Treg was restored.
The identification of Treg subsets by Foxp3þ expression requires intracellular staining and cell permeabilization, making the isolation of live Treg cells and their functional analysis impossible. CD25 expression has previously been used for purification of live Treg for functional studies, but is also not optimal since CD25bright, CD25dim, and CD25-populations are not clearly defined. Therefore we have investigated the use of CD39 to define subsets of Foxp3þ cells and find that CD4 þ CD25þþCD39 þ CD45RO þ ells are effector Treg, whilst naïve Treg are characterized as CD4 þ CD25þþCD39-CD45RO-. Activated Foxp3þ effector cells are CD4 þ CD25 þ CD39-CD45ROþ. Conclusions: The frequencies of both effector Treg and naïve Treg are impaired in AS and RA patients, and are partially restored by anti-TNF treatment. CD39 expression can be used to identify Treg subsets, and will facilitate future functional studies of Treg in health and disease. Disclosures: The authors have declared no conflicts of interest. Background: Granulomatosis with polyangiitis (GPA) and SLE are autoimmune diseases which develop due to failure of immune selftolerance. T follicular helper cells reside in lymphoid tissues within the germinal centres and are a minor subset of CD4 þ T cells in peripheral blood. They have been linked with autoimmunity in animal models, where they are thought to reduce the threshold for B-cell survival. In contrast, T regulatory cells are able to suppress autoimmune responses.
ALTERATIONS IN CIRCULATING T FOLLICULAR HELPER CELLS AND T REGULATORY CELLS IN AUTOIMMUNE RHEUMATIC DISEASES TREATED WITH B-CELL DEPLETION THERAPY: RITUXIMAB
Hypothesis: In GPA and SLE there is a decrease in the T regulatory (TREG) cell population and an increase in the circulating T follicular helper (cTFH) cell population during active disease. B-cell depletion therapy may correct disease-associated changes of cTFH and TREG frequencies in autoimmune disease patients who have a positive clinical response. Methods: An observational longitudinal study. Demographics and baseline characteristics of 5 GPA pre-rituximab patients, 5 GPA controls, 10 SLE pre-rituximab patients, 10 SLE controls and 15 healthy controls recruited to date have been analysed. GPA and SLE patient pre-rituximab and post-rituximab 1 month, 3 month and 6 month clinical assessments and fluorochrome-labelled antibody cell staining (FACS) flow cytometry of isolated peripheral blood mononuclear cells have been analysed for CD4 þ CD25highCD127low T regulatory (TREG) cells, CD3 þ CD4 þ CXCR5highPD1high circulating T follicular helper (cTFH) cells and B lymphocyte subsets. Statistical analysis by GraphPad Prism 4. Results: Mean age of GPA patients ¼ 51 years (38-67), SLE patients ¼ 42 years old Background: The strong association of the human leucocyte antigen HLA-B27 (B27) with the SpAs, particularly with AS, was discovered more than four decades ago, yet the role of B27 plays in disease remains unclear. Our research group discovered that B27 free heavy chains (B27 HC) can form dimers (B272) and/or non-classical B27 molecules (NC-B27), which can bind innate immune receptors in nonconventional way, compared with other MHC class I molecules. We therefore investigated the pathogenic role for these forms of B27 in AS.
Methods: We used a novel HD6 antibody, generated against B272, alongside the conventional HC10 and ME1 antibodies to examine surface expression of NC-B27 in AS patient and healthy control primary cells and transduced cell lines using flow cytometry, confocal microscopy and immunoprecipitation techniques.
Results: Confocal microscopy experiments revealed that NC-B27 can form clusters at the cell surface of B27-transduced cells.
Immunoprecipitation data demonstrated that NC-B27 are present at the surface of the B27-positive cells more abundantly in a higher molecular weight form ($80 kDa) compared with the monomeric form ($45 kDa). Moreover, low pH treatment of cells can further induce both forms of B27. HD6 did not stain monocyte-derived dendritic cells (moDCs) from AS patients or healthy controls, irrespective of moDC maturation state. However, LPS treated AS moDCs expressed higher levels of HC10-reactive molecules than those from healthy controls. HD6 and HC10 staining can be induced in AS moDCs by low pH treatment.
Conclusions: Confocal microscopy data brought additional insight into the segregation patterns of classical and non-classical B27 molecules at the cell surface. We showed by flow cytometry and immunoprecipitation that HC-B27 expression on AS moDCs is significantly increased compared with healthy controls. Furthermore, we showed that low pH treatment can induce HD6 and HC10 staining on the B27 positive cells.
Disclosures:
The authors have declared no conflicts of interest.
DIFFERENTIAL GENERATION OF CC CHEMOKINES AT MICROVASCULAR ENDOTHELIAL CELLS OF BLOOD AND LYMPHATIC VESSELS UNDER INFLAMMATORY CONDITIONS
Background: Rheumatoid arthritis (RA) is a chronic inflammatory condition of the joints in which the accumulation of leucocytes in the synovial membrane results in development of inflammation, joint destruction and pain. Chemokines and their receptors play a central role in this process. GPR15/BOB is a member of the chemokine receptor family whose ligand is unknown. We previously found expression of GPR15/BOB mRNA to be up-regulated in RA compared with non-RA synovial tissue with the receptor expressed on macrophages. GPR15/BOB was observed on leucocytes in peripheral blood, where expression was up-regulated on monocytes and neutrophils in RA patients in comparison with healthy controls. Identification of a ligand for GPR15/BOB would allow investigation of its expression in the sub-compartments of the joint and determination of the functionality of GPR15/BOB on leucocytes in the context of RA. Up-regulation of expression of GPR15/BOB in RA may be linked to migration of leucocytes into affected joints. Methods: In this study a calcium flux assay was used to investigate GPR15/BOB receptor activation when a GHOST cell line expressing GPR15/BOB was stimulated with a chemokine panel. Fluorescence flux generated in GHOST cells expressing GPR15/BOB was compared with GPR15/BOB negative cells. We aimed to identify chemokine (s) stimulating calcium flux via the GPR15/BOB receptor and thus to identify the ligand for GPR15/BOB. Cell-surface chemokine receptor expression profiles on the GHOST cells were examined by flow cytometry.
Results: A panel of 41 chemokines was screened in the calcium flux assay producing differential levels of flux with different chemokines and between cells positive or negative for GPR15/BOB expression. Examination of endogenous cell-surface receptors on GPR15/BOB positive cells demonstrated presence of CCR1,2,4 and 5; and CXCR1,2 and 3 (all with MFI > 4.5), likely accounting for the fluorescence flux observed with cognate chemokine ligands to these receptors in the calcium flux assay. CCR3 was initially observed at very low level on the GHOST cells (MFI ¼ 1.5) suggesting its ligand CCL11 which produced greater flux in GPR15/BOB positive compared with GPR15/BOB negative cells, may be signaling through GPR15/ BOB. However further analysis of CCR3 expression using an alternate antibody demonstrated that the receptor was in fact present on the cells (MFI ¼ 27.5) and at comparable levels to GPR15/BOB (MFI ¼ 24.7). Conclusions: Whilst initial observations suggested that CCL11 may be signaling through the orphan GPR15/BOB receptor in the absence of CCR3; further investigation demonstrated that CCR3 was present on GHOST cells suggesting that CCL11 was in fact signaling through CCR3. Disclosures: The authors have declared no conflicts of interest. Background: Abatacept (CTLA-4Ig) is a biologic DMARD that blocks T-cell activation at the level of costimulation. This activity occurs in conjunction with blockade of the CD28-CD80/CD86 pathway which is regarded as the predominant source of T-cell costimulatory signalling. Variability in RA patient responses to abatacept implies differential CD28-costimulation contributions to T-cell activation; however the mechanisms underlying this are not fully understood. Therefore, the identification of factors that determine abatacept sensitivity or resistance can provide a basis upon which to appropriately target treatment. Methods: CD4 þ CD25-T cells were isolated from PBMCs derived from healthy donors and were cultured for 5 days in the presence of anti-CD3 or Toxic Shock Syndrome Toxin (TSST)-1 as T-cell receptor (TCR) stimuli and either CD80/CD86 transfected CHO cells or allogeneic human monocyte derived dendritic cells (DCs) as sources of costimulation. The impact of abatacept upon T-cell activation in these stimulations was identified in terms of effects upon proliferation of T-cell responders. Results: When T-cell activation was driven by soluble anti-CD3 and CD80 or CD86 transfectants, abatacept facilitated effective blockade of T-cell activation. However, when T-cell activation was mediated by soluble anti-CD3 in conjunction with DCs, CD80/CD86 saturating concentrations of abatacept had limited effect upon T-cell proliferation, although the level of inhibition became more significant at lower DC:T-cell ratios. This apparent abatacept resistance was however abrogated at significantly reduced anti-CD3 concentrations. Similarly, in a model of T-cell activation driven by TSST-1, which displays affinity for T cells expressing the Vbeta2 chain, high affinity T-cell responders (Vbeta2þ) were resistant to abatacept at high doses of TSST-1 but were more inhibited with decreasing TSST-1 concentrations. Conversely, the activation of low affinity TSST-1 responders (Vbeta2-) was inhibited by abatacept regardless of TSST-1 concentration. Conclusions: These data are consistent with a model in which T-cell activation occurs when a signalling threshold composed of variable proportions of TCR and costimulatory signalling is achieved. The efficacy of abatacept may therefore be limited by factors that enhance the strength of TCR stimulation. As such, in a situation in which TCRs display a degree of cross-reactivity that is associated with a range of affinities to a specific peptide, abatacept is likely to be most potent in preventing activation of low affinity T cells whilst high affinity T cells bypass the requirement for CD28 costimulatory signalling. Disclosures: The authors have declared no conflicts of interest.
ABATACEPT SENSITIVITY IS DETERMINED BY FACTORS THAT DEFINE THE STRENGTH OF T-CELL

DIMINISHED ENVIRONMENTAL OXYGEN ALTERS MEMORY T-CELL RESPONSES TO STIMULATION, WITH SEVERE HYPOXIA DEPRESSING BOTH CYTOKINE PRODUCTION AND TH2 CELL DEVELOPMENT
Elizabeth Clay 1 , Rachel Bayley 1 , Martin Fitzpatrick synovitis negatively correlates with the amount of oxygen measured in the joint. Given the important contribution made by lymphocytes to synovial inflammation we have investigated the effect of different oxygen levels on CD4þ memory T helper cell phenotype and function. Methods: Several oxygen levels were selected for investigation. 8.5% oxygen was investigated as that which most closely reflects oxygen levels of the healthy joint. This was compared with 3% oxygen, which is the oxygen level reported to be present in the rheumatoid joint. To investigate the effect of severe hypoxia, constant 1% oxygen and 1% oxygen with exposure to higher oxygen levels (as a model of reperfusion injury) were investigated. Experiments were also performed at 21% oxygen as a comparison with most in vitro experiments. Memory CD4þ T cells were isolated from multiple healthy donors using Miltenyi's Memory CD4þ T Cell Isolation Kit 130-091-893. These cells were placed in a Whitley H35 Hypoxystation equilibrated with the required oxygen level and incubated for 24 h before stimulation with plate-bound anti-CD3/CD28. Assessment of T-cell phenotype was performed after 48 h stimulation. ELISAs were performed to assess the production of a number of cytokines. Flow cytometry panels were developed to assess markers for helper T-cell phenotype towards Th1, Th2, Th17 and regulatory T-cell phenotypes. Additional panels were generated to assess levels of activation markers including CD69. Proliferation was assessed by CFSE loading.
Results: At 3% oxygen, IFN production was increased compared with that seen at higher oxygen levels. Surface marker and transcription factor analysis revealed that at 3% oxygen and below, CD4þ memory T cells potentially have a more inflammatory phenotype. In contrast, at the physiologically healthy oxygen level of 8.5%, CD4þ memory T cells showed a reduced pro-inflammatory phenotype with a significant increase in CCR4 þ GATA3 þ cells (markers associated with a Th2 phenotype). Cells stimulated at 3% oxygen and below had increasing numbers of cells that had entered more rounds of proliferation. These cells also had increased intensity of expression of CD69.
Conclusions:
The rheumatoid joint is hypoxic in nature, and lack of oxygen is known to impact on immune cell function. We have found that at 3% oxygen, the average oxygen level observed in rheumatoid joints, CD4þ memory T-cell pro-inflammatory cytokine production is increased compared with other oxygen levels. At healthier oxygen levels of 8.5% oxygen, CD4þ memory T cells revealed a more Th2-like phenotype. This suggests that the low oxygen levels in the inflammed joint may contribute to the perpetuation of the immune inflammatory processes driving RA. Disclosures: The authors have declared no conflicts of interest. 
THE ARTHRITIS-ASSOCIATED
Department of Medical Sciences, University of Cagliari, Cagliari, Italy
Background: We hypothesized that differential interactions with KIR and LILR immune receptors could contribute to the association of HLA-B*27:05 and lack of association of HLA-B*2709 with AS. HLA-B*27:05 heavy chain dimers (B272) and b2 m-associated heterotrimers bind KIR3DL1 and LILRB2 receptors. By contrast only HLA-B*27:05 dimers bind KIR3DL2. Thus, we compared formation of b2 m-free free heavy chains (FHC) including B272 by LA-B*27:05 and -B*27:09 and their interaction with KIR and LILR. Methods: We studied formation of HLA-B*27:05 and HLA-B*27:09 heterotrimers and FHC forms in vitro and in transfected cells. We studied HLA-B*2705 and -B*2709 interactions with KIR3DL1, KIR3DL2 and LILRB2 by FACS staining with class 1 tetramers, LILRB2Fc and KIR3DL2Fc proteins and using KIR3DL2 and LILRB2 reporter cells and KIR3DL2-expressing NK and T cells. We studied LILRBFc staining of cell lines by confocal microscopy. We measured KIR expression on peripheral NK and CD4 T cells from 18 HLA-B*27:05 AS patients, 8 HLA-B27 negative and 12 HLA-B*27:05þ and HLA-B*27:09þ healthy controls by FACS staining. Results: HLA-B*27:09 formed less B272 and FHC than HLA-B*27:05. HLA-B*27:05 stimulated KIR3DL2CD3"-reporter T cells more and stained more strongly with LILRB2Fc than HLA-B*27:09. HLA-B*27:05 promoted KIR3DL2þ leucocyte cell survival more strongly than HLA-B*2709. HLA-B*27:05 and -B*27:09 dimer tetramers stained KIR3DL1, KIR3DL2 and LILRB2 equivalently. Increased proportions of NK and CD4 T cells expressed KIR3DL2 in HLA-B*27:05þ AS patients compared with HLA-B*27:05þ, -B*27:09þ and HLA-B27-healthy controls. Conclusions: Differences in the formation of FHC ligands for KIR3DL2 and LILRB2 by HLA-B*27:05 and B*27:09 could contribute to the differential association of these alleles with AS. Disclosures: The authors have declared no conflicts of interest. There are four eIF2a kinase candidates that might contribute to eIF2a phosphorylation; the aim of this work was to identify whether PKR, a cytosolic eIF2a kinase, is required to induce the ISR and subsequent pro-inflammatory reprogramming of the host following intracellular bacterial infection. Methods: Peripheral blood monocytes from healthy volunteers were differentiated into DC for 6 days using IL-4 and GM-CSF. HeLa or DC were infected with Chlamydia trachomatis (CT) or Chlamydia muridarum (CM). Transcriptional analysis was carried out by Q-RT-PCR and protein was assessed by western blot. Cytokine secretion was determined by ELISA. ROS generation was assayed by DCF staining and flow cytometry.
CYTOKINES AND INFLAMMATORY MEDIATORS
Results: Chlamydia infection induced eIF2a phosphorylation and expression of transcription factors ATF4/ATF3, which are associated with ISR activation. PKR was identified as the eIF2a kinase responsible, since infection of human DC or HeLa cells with CT or CM induced phosphorylation of PKR indicating PKR activation. Furthermore, chemical inhibitors of PKR activity prevented the induction of the ISR. To examine whether ROS production was a critical signal for PKR activation, we infected DC and HeLa cells in the presence of the anti-oxidant NAC, or specific chemical inhibitors of NOX-2 derived ROS. Blocking ROS with NAC had no effect on PKR activation or CHOP induction, and inhibition of NOX-2 had no effect on cytokine production. Significantly, inhibition of PKR activation reduced IL-23, IL-1b and IL-6 secretion.
Conclusions: Detection of intracellular bacterial pathogens such as
Chlamydia results in ROS independent activation of PKR that stimulates IL-1b and IL-6 production. Furthermore, PKR acts as an eIF2a kinase, inducing the ISR and initiating pro-inflammatory transcriptional activity, leading to IL-23 production. We propose PKR to be a novel, crucial modulator of pro-inflammatory signalling during intracellular bacterial infection, and suggest PKR as a therapeutic target in preventing inappropriate inflammation in pathogen induced conditions such as reactive arthritis. Disclosures: The authors have declared no conflicts of interest. Background: Rheumatoid arthritis (RA) is a polygenic disorder usually arising from combined genetic predisposition and environmental influences with associated dysfunctional immune responses. Dysregulation of specific microRNAs (miRs) has been implicated in RA pathogenesis. Our aim was to investigate how two different molecular pathways with a role in RA pathogenesis, namely the unfolded protein response (UPR) and Toll-like receptor (TLR) signalling, may affect the expression of miRs. Furthermore, we wanted to specifically examine the role of activation of X-box binding protein 1 (XBP1), a transcription factor which has been associated with both TLR signalling and ER stress in this process. The active form of XBP1 is referred to as spliced XBP1 (sXBP1). Methods: Quantitative real-time polymerase chain reaction (qPCR) in High-throughput TaqMan Human MicroRNA Cards was used to generate miR expression profiles (total of approximately 700miRs) in fibroblast-like synoviocytes (FLS) isolated from biopsies of patients with RA, treated with TLR ligands and ER stress inducers, including thapsigargin. Osteoarthritis FLS (OA FLS) were used as control. Quantitative PCR, using SYBR green assay, was performed using specific primers to detect the expression of sXBP1. RA FLS were then treated with different TLR2 and 4 ligands, with or without specific TLR inhibitors. In addition, evaluation of the levels of expression of specific individual miRs was also measured using Taqman assays in the treated RA FLS. Results: For the microRNAs profiling data analysis, the fold change in miR expression in untreated cells compared with treated cells was calculated. Only miRs that demonstrated a reduction of at least half, or an increase of at least double were further analysed. The miRs were then split into the following groups: a) those with altered expression in response to TLR ligands, b) those with altered expression in response to ER stress stimulation only and c) those that were differentially affected by TLR or ER stress stimulations. We found that TLR2 and 4 signalling associated with XBP1 activation affects three individual miRs (155, 146a, 346) irrespective of ER stress. Conclusions: MicroRNAs regulation has been involved in the pathogenesis of RA. Stimulation of RA FLS with specific TLR ligands resulted in the activation of XBP1 as well as dysregulation of the expression of specific miRs. Next, we would like to investigate the involvement of specific miRs in disease progression and also identify their targets; antagomirs will be used to confirm their inflammatory involvement. Institute of Musculoskeletal Science, University of Oxford, Oxford, UK Background: Several studies have shown that weight bearing leisure time physical activity has a beneficial effect on bone mineral density (BMD). However, far fewer data are available relating occupational physical activity to BMD. We addressed this question using the Hertfordshire Cohort Study, a cohort of 1000 men and women in whom occupational activity exposure and BMD were available. Methods: We studied 498 men and 468 women born in Hertfordshire between 1931 and 1939 who still lived there in adult life. These individuals attended a local clinic where a health questionnaire was completed, detailing past medical history, drug history (including HRT use) cigarette and alcohol consumption, occupational and leisure physical activity. Anthropometric data were recorded. Bone densitometry (DXA) was performed at the femoral neck using a Hologic QDR 4500 instrument. Measurement of lumbar spine BMD was not considered in this analysis due to the possible confounding effects of lumbar spine OA. Full ethical approval and patient consent were obtained. Analysis of occupational exposure was achieved through categorization of standing, lifting, sweating and manual work by tertile according to the number of years of exposure. Results: Of the 498 men and 498 women recruited, the analysis was confined to 498 men and 402 women to exclude women who had not worked for 20 years or longer. The mean (S.D.) age of participants was 64.8 (2.54) in men and 66.5 (2.55) in women. A higher BMI was associated with a greater hip BMD in both sexes (P < 0.0001). In women, current HRT use was also associated with a higher BMD (P < 0.0001). In this cohort, using these crude measures of occupational activity exposure, there was no residual effect of occupational exposure after adjustment for confounders (age, BMI, smoking status, alcohol consumption, dietary calcium intake and years since menopause/ use of hormone replacement therapy among women). Conclusions: These data suggest that enquiry regarding occupational exposure to standing, lifting, sweating or manual work would not be useful additions to the functional enquiry of patient being investigated for possible osteoporosis. Disclosures: The authors have declared no conflicts of interest. Background: Socioeconomic deprivation may impact upon RA due to impaired access to healthcare/services, lifestyle factors or comorbidities. We aimed to assess whether early RA outcomes were associated with socioeconomic deprivation. Methods: The Early Rheumatoid Arthritis Network (ERAN) is in inception cohort of early RA from 22 outpatient centres in UK and Eire. Social deprivation index (IMD2007) was measured from the postcodes of 900 people covering 73% of the cohort. IMD2007 is the current UK government index of deprivation, from the geoconvert website (geoconvert.mimas.ac.uk). A subset were analysed for radiographic progression. Data analysis used odds ratios (ORs), adjusted OR (aOR), 95% CI and logistic regression. The top England/Wales national tertiles were used as the most-deprived group, and significance was taken if P < 0.05. Results: Within ERAN, 227 people resided within the most-deprived tertile of England and Wales. 414 people and 259 people lived in the middle and least deprived regions, which were pooled for analysis. People in the deprived areas showed higher CRP, pain, disability and smoking; and poorer mental health and vitality. At baseline, HAQ disability score was higher in people from deprived areas (median (IQR) deprived: 1.3 (0.7-1.9) vs not: 1.0 (0.4-1.5), P < 0.001), and at 2 years (deprived: 1.4 (0.4-1.8) vs not: 0.9 (0.3-1.5), P < 0.001). DAS28 showed no significant differences at baseline (median (IQR) deprived 4.8 (3.7-5.9) vs not: 4.5 (3.4-5.7), P ¼ 0.199) or 2 years (deprived: 3.8 (2.6-5.1) vs not: 3.5 (2.3-4.7), P ¼ 0.068). At 2 years, deprivation was also associated with higher HAQ after univariate analysis (OR 1.91, 95% CI 1.24, 2.95), but not DAS28 (OR 1.24, 95% CI 0.80, 1.93) . After logistic regression higher deprivation was associated with 2 year HAQ (see Table 1 ). Similar analysis did not yield a significant association with 2 year DAS28 (OR 1.27, 95% CI 0.72, 2.26, P ¼ 0.409). Univariate analysis of radiographic progression (n ¼ 161) did not show an association with deprivation. Conclusions: Socioeconomic status may be associated with RA disability. This was not explained smoking or DAS28. Further research should address how treatments to reduce disability can be better targeted to people with RA living in regions of greater deprivation. Background: Scoliosis is lateral curvature of the spine !10 degrees, as measured on a standing spinal radiograph. The current knowledge about determinants of adolescent idiopathic scoliosis (AIS) is derived from studies in individuals, families with disease, or cases. However, there are no published studies that have investigated determinants of scoliosis using a prospective cohort design, making the establishment of cause and effect difficult. Several large population-based cohorts exist throughout the world with a wide range of clinical, biological and genetics data already collected, and while spinal imaging with traditional radiographs is not generally collected in these cohorts, total body dual energy X-ray absorptiometry (DXA) has been routinely collected at repeated time points for the study of determinants of bone size and density. We therefore wished to develop and validate a novel method of identifying scoliosis on total body DXA scans. Methods: Scoliosis was identified on total body DXA scans by triaging to distinguish true curves from positioning errors, followed by a modified-Ferguson method to measure angles. Precision was assessed on 174 children from the Avon Longitudinal Study of Parents and Children (ALSPAC), who underwent repeat DXA scans at age 15, 2-6 weeks apart. In addition, precision of angle estimation was evaluated on 20 scans measured 5 times. To evaluate accuracy, angle size was compared with spinal radiographs in 13 individuals with known scoliosis. Subsequently, this method was applied to estimate scoliosis prevalence rates and curve patterns from DXA scans previously obtained in 7298 ALSPAC participants at aged 9 and 5122 at 15.
CHARACTERIZATION OF ENZYMES INVOLVED IN NICOTINAMIDE ADENINE DINUCLEOTIDE BIOSYNTHESIS IN RHEUMATOID ARTHRITIS SYNOVIUM AND CYTOKINE-STIMULATED SYNOVIAL FIBROBLASTS
PEOPLE LIVING IN DEPRIVED AREAS DISPLAY GREATER DISABILITY AFTER 2 YEARS OF RHEUMATOID ARTHRITIS: THE ERAN COHORT
Results: There was substantial agreement in identifying those with scoliosis on repeat DXA scans taken 2-6 weeks apart (Kappa of 0.74, 95% CI 0.59, 0.89). 95% of repeat angle measures were within 5 degrees. Angle size was underestimated by approximately 40%. Prevalence of scoliosis !10 degrees in ALSPAC was 0.3% at aged 9 and 3.5% at aged 15, and was higher in girls at both time points. Mean (S.D.) curve size was 12 (4) at aged 9 years, and 15 (7) degrees at aged 15.
Conclusions:
We have developed and validated a novel method for identifying scoliosis from DXA scans. Comparison with prevalence data using more established techniques suggests our method provides valid estimates of scoliosis prevalence in population-based cohorts.
Disclosures: The authors have declared no conflicts of interest. Background: Osteoporosis (OP) is diagnosed based on a T score of <-2.5 in either the femoral neck or the lumbar spine. This is based upon the number of standard deviations away from the average T score in a young healthy woman. 1 This was based upon data in women but may be an erroneous use in men who are at only half the risk of developing OP compared with women. However, 1 in 4 men over 50 years old will suffer a fragility fracture and so investigating the risk for developing fragility fractures in men is important. The aims of this study are 2-fold: (i) to identify in which site (lumbar spine or femoral neck) best predicts fracture in men; and (ii) which T Score threshold best predicts fracture. Methods: Male patients attending a District General Hospital for DEXA scanning between April 2004 and September 2010 were included in the study. BMD and T scores were measured in the L1-L4 vertebrae and the femoral neck. Of these patients, two groups were identified, a group who had sustained a fracture and a non-fracture group. The influence of femoral neck T scores was compared with the influence of T scores in L1-L4 using a logistic regression model. In addition, a receiver operator characteristics (ROC) curve was used to assess how strongly T scores in these areas predicts fracture. The mean T score in these two areas were then divided into 10 thresholds starting at À1 progressing in 0.25 increments. Using a logistic regression model, these different thresholds were then used to predict fracture in order to see which threshold was the most strong predictor. Results: Data on 2564 males were analysed of which 738 (29%) had sustained fractures, baseline demographics are shown in Table 1 . The area under the ROC curve in the lumbar spine is 0.63 and is 0.61 in the femoral neck. The T score threshold which most strongly predicts fracture is <-2.0 in the lumbar spine, with odds ratio 2.62 (95% CI 2.11, 3.25) and an area under the ROC curve 0.596.
T SCORE THRESHOLDS AS PREDICTORS OF FRACTURES IN MEN
Conclusions:
The results of this study have shown that the BMD in the lumbar spine is more strongly associated with fracture than the femoral neck. In terms of which cut-off for T score most strongly suggests fracture, the results of this study have found that a T score of less than À2.0 in the lumbar spine is the best predictor. This is the first time this has been demonstrated. Background: In RA, clinicians recognize a pattern of high global score, high tender joint count, but low swollen joint count and low acute phase response. These patients are often thought to have central sensitization rather than high disease activity and this may alter treatment decisions. This pattern is related to high DAS28-P index (the proportion of DAS28 from tender joints and global assessment) which predicts pain. We aimed to determine whether DAS28-P predicted radiographic changes in RA. Methods: The Early Rheumatoid Arthritis Network (ERAN) is in inception cohort of early RA from 22 outpatient centres in UK and Eire. Radiographs of hands and feet were scored by one blinded assessor using the van der Heijde modified Sharp system. Radiographs from baseline and 2-4 years were analysed for progression, erosions and joint space narrowing (JSN) using odds ratios (OR), adjusted OR (aOR), 95% CI and logistic regression. Above/below median change in score was analysed and significance was P < 0.05. Results: 459 people had baseline radiography data available and 166 provided follow up data for analysis. At baseline the median (IQR) age was 58 (49-69) years, DAS28 4.6 (3.5-5.7) and DAS28-P 0.45 (0.41-0.50); 64% were female and 62% seropositive.
At baseline, the median (IQR) radiographic score was 6 (3-12) with erosions 2 (0-5) and JSN 4 (2) (3) (4) (5) (6) (7) (8) . At follow up, the radiographic score was 14 (7-23) with erosions 5 (2-10) and JSN 7 (4-13). The changes in radiographic score were 6 (3-12), erosions were 3 (1-6) and JSN were 3 (1-7) (P < 0.001).
High radiographic score at baseline predicted above median progression in total radiographic score (aOR 2.03, 95% CI (1.15, 3.59) , P ¼ 0.015). Above median progression of erosions was associated with lower DAS28-P and better mental health (Table 1) , and higher JSN progression was not associated with baseline variables. Conclusions: Participants where patient-reported components contribute a greater proportion of DAS28 display less radiographic progression but are known to have worse pain prognosis. The relative contributions of DAS28 subcomponents may be important indicators for the balance needed between disease modifying and pain management therapies. Prospective clinical trials would be required to determine the utility of DAS28-P in treatment stratification. Background: Previous research has suggested that the severity of RA has decreased over time. This study examines the pattern of disease severity in patients with inflammatory polyarthritis (IP) at time of registration into the Norfolk Arthritis Register (NOAR). Methods: NOAR is a primary-care-based cohort of adults with recent onset IP (!2 swollen joints lasting for >4 weeks). Disease related variables assessed at baseline include 51-swollen and tender joint count and the Health Assessment Questionnaire (HAQ). Blood is collected and C-reactive protein (CRP), Rheumatoid Factor (RF), and Anti-Citrullinated Peptide Antibodies (ACPA) are measured. The DAS28 (Disease Activity Score) is calculated using CRP level. In this study, patients with a symptom duration of <2 years at baseline were grouped into four cohorts depending on the NOAR recruitment phase: (1) 1990-1994; (2) 1995-1999; (3) 2000-2004; (4) Background: PsA is a chronic inflammatory arthritis associated with psoriasis. PsA is thought to arise as a result of an environmental trigger in a genetically susceptible individual and multiple genetic factors contribute towards disease susceptibility. Based on family studies there is a strong genetic component to risk for developing PsA with heritability estimates 80-100%. There is evidence from subgroup analysis of a genome wide association study (GWAS) that a locus on chromosome 5q31 is specifically associated with PsA and not psoriasis. This result has been replicated in two independent studies. A recent GWAS performed in a UK population (unpublished data) has refined and strengthened this association to a region 500 kb upstream of the original GWAS. There is however substantial linkage disequilibrium within this region necessitating the need for functional data to determine the causal variant. Methods: Genotype data for a total of 1182 817 single nucleotide polymorphisms (SNPs), which includes the 5q31 region, were available for 836 PsA cases and 4770 controls (www.wtccc.org.uk). Genotyping was performed as part of a wider GWAS using the Illumina 660 W quad BeadChip and Affymetrix Genome-Wide Human SNP Array 6.0 arrays. A strict quality control process was applied to the dataset followed by single point analysis using the Armitage test for trend. The lead SNP from the 5q31 region was selected and SNPs highly correlated (R2 > 0.8, 1000 genomes project) to the lead SNP were identified. ENCODE and expression quantitative trait loci (eQTL) data were searched, using publicly commercial databases, to explore evidence for transcription factor binding, DNase peak and eQTL. Results: The lead SNP rs4705928 (P ¼ 5.77 x 10 -6 OR ¼ 0.78) lies within an intergenic region and does not overlie a known functional site. 59 highly correlated SNPs were discovered. Bioinformatic interrogation revealed 13 SNPs with eQTL and transcription factor (TF) binding/DNase peak evidence, 1 SNP with TF binding and DNase peak evidence with predicted binding motif alterations and DNase footprint, 4 SNPs with TF binding and DNase peak evidence and 9 However, much remains to be established, not least the impact of these modifications in individual cell types implicated in the disease process. We therefore performed unbiased genome-wide DNA methylation profiling in purified T-cell populations from patients with RA. Methods: CD3 þ T cells were isolated from the peripheral blood of 12 patients with rheumatoid factor positive established RA and also from 12 age-and sex-matched healthy subjects (all non-smoking, Caucasian females). Genomic DNA was extracted and treated with sodium bisulfite, followed by hybridization to 2 Infinium HumanMethylation450 arrays (Illumina) for quantification of genomewide DNA methylation at over 450,000 CpG loci. Each 12-sample array consisted of 6 patient samples and 6 healthy samples. Bisulfite pyrosequencing and/or bisulfite cloning and sequencing were used to validate methylation data. Gene expression was quantified using realtime RT-PCR. Data were processed using GenomeStudio software and analysed using NIMBL software. Results: In both cases, independent analysis of each array (6 RA patients vs 6 healthy subjects) revealed approximately 700 CpGs, representing approximately 450 genes, that were differentially methylated (change in b-value ! 0.1) between patients and healthy subjects. The majority (60%) of sites was hypermethylated and 55-60% were associated with a CpG Island or the surrounding shores/shelves. Analysis incorporating all 24 samples together (12 RA patients vs 12 healthy subjects) identified 78 differentially methylated CpGs, approximately 60% of which were hypermethylated or were associated with a CpG Island or island shores/shelves. These 78 CpGs, which represented 46 different genes, included 11 discrete differentially methylated CpGs which mapped to the promoter region of a single gene, identified as the dual specificity phosphatase DUSP22. These 11 CpGs were hypermethylated in 10 of the 12 RA patients ($50% increase in methylation). Despite the increase in methylation observed, this was not associated with a reduction in DUSP22 gene expression in RA patients. There was also no difference in DUSP22 gene expression between patients and healthy subjects. Background: Preventing RA is a key research goal. The improved characterization of RA's risk factors raises the possibility they could be combined to identify individuals at a high risk of disease in whom preventative strategies may be evaluated. Our main aim was to develop a prediction model capable of identifying such high risk individuals. Our secondary aims were to establish if our models better identified those at risk of younger-onset RA (YORA) and more severe disease, as evidence suggests that some susceptibility variants influence RA age of onset and severity. Methods: Our prediction models combine odds ratios (ORs) for 15 four-digit/10 two-digit HLA-DRB1 alleles, 31 non-HLA single nucleotide polymorphisms (SNPs) and ever smoking in males to classify an individual's risk of seropositive RA. Our novel modelling approach employs CIs to classify disease risks using computer simulation. We developed HLA, HLA 31-SNP and HLA-smoking models to assess the impact of different factors on prediction. Additional smoking data improved predictive abilities (P ¼ 0.003651 WTCCC; P ¼ 0.00034 UKRAG); additional SNP data improved prediction in WTCCC only (P ¼ 0.0118). Despite high AUCs only a minority of individuals had substantially elevated RA risks. The HLA model better identified those at risk of YORA: a significant, positive correlation was seen between the weighted genetic risk score generated by this model and a younger onset age (WTCCC: b ¼ 0.022, P ¼ 0.0008; UKRAG: b ¼ 0.024, P ¼ 0.0004). Smoking significantly associated with an older onset age in UKRAG (P ¼ 0.0009); a non-significant association was observed in WTCCC (P ¼ 0.0585). Conclusions: Combined information on HLA-DRB1 alleles and smoking provides informative risk prediction for RA. As only a minority of individuals are at substantially elevated risks our models are not suitable for population screening but may have clinical utility if focused in a priori high-risk groups such as those with family histories of RA. Whilst HLA-DRB1 alleles associate with YORA, smoking may predispose to older onset disease. Further work is needed to define risk factors with large effect sizes for incorporation within our modelling. Disclosures: The authors have declared no conflicts of interest. Background: Scleroderma or systemic sclerosis (SSc) is a rare complex disease which affects approximately 2 in every 100,000 people in the UK. The exact aetiology of SSc is not fully understood, however the pathogenesis of SSc has shown dysregulation of the vascular and immune systems, both leading to fibrosis. To date, a number of candidate gene studies and Genome-wide association studies (GWAS) have shown the replication of a number of key loci. However, due to the heterogeneity of SSc, further genetic analysis is needed to fully understand the genetic component of this disease.
JNK-1 SHOWS AN ASSOCIATION WITH ACA AND ARA POSITIVE SSC PATIENTS
Here we genotyped polymorphisms across JNK-1 (c-Jun N-terminal Kinase 1) to ascertain a potential pathological role in SSc. Methods: Methods: 728 SSc cases and 260 healthy controls were genotyped for nine JNK-1 polymorphisms as part of a larger genotyping study. All patients and controls were of Caucasian decent and were categorized according to three mutually exclusive autoantibody status: anti-topoisomerase1 (ATA), anticentromere (ACA) and antiRNA-polymerase (ARA). Patients were further classified into sub-phenotypes according to major organ involvement; pulmonary fibrosis (assessed by HRCT and lung function test with a restrictive pattern), pulmonary arterial hypertension (defined as an elevation in the mean pulmonary artery pressure >25 mmHg with normal pulmonary capillary wedge pressure (< 15 mmHg) on right heart catheterization) and renal crisis (defined by a rapidly progressive renal failure, new onset accelerated hypertension). All genotyping was performed by the KASP system (allele specific PCR, KBioscience, UK). All genotype data and sub-phenotype analysis was performed using PLINK.
Results: Our cohort consisted of 63 (9%) patients with renal crisis and 112 (15%) with pulmonary arterial hypertension. 155 (21%) patients were positive for ATA, 255 (35%) patients were positive for ACA and 140 (19%) patients were positive for ARA. The SSc cases and the healthy controls were genotyped and all SNPs and individuals passed quality control checks for Hardy-Weinberg equilibrium (P ¼ 0.05) and missingness (P ¼ 0.1). An overall case-control analysis was performed using PLINK, of which no association was found in any individual SNP or haplotype. However, sub-phenotype analysis showed associations between SNP rs2289805 with ACA (P ¼ 0.012, OR ¼ 0.64) and ARA (P ¼ 0.002, OR ¼ 1.73); hence demonstrating the dual role of SNP rs2289805 in SSc with a protective effect in ACA positive patients and a risk effect in ARA.
Conclusions:
We report a novel association with SNP rs2289805 in both ACA and ARA positive SSc patients. JNK-1 is a transcription factor which enhances collagen gene activities through the induction of TGF-b. Polymorphisms in JNK-1 can lead to a deregulation of expression of collagen associated genes leading to increased collagen formation and fibrosis. These data suggest JNK-1 to be a good candidate gene in SSc and warrants further investigation. Disclosures: The authors have declared no conflicts of interest. Background: Recent segmental duplication affecting the FCGR locus on chromosome 1 has led to structural variation and ambiguous mapping of underlying genetic variants. Consequently, the region is misrepresented in SNP databases, has been untested by genome wide association studies and dismissed as a potential contributor to genetic predisposition, despite encoding receptors which are known to bind IgG-containing immune complexes and autoantibodies. A recent large-scale study identified a polymorphism close to FCGR2A with reproducible association with RA. Methods: Gene specific resequencing of paralogous FCGR genes was performed in a panel of 32 controls. A reduced number of confirmed FCGR2A markers were selected and genotyped in 1959 RA patients and 1120 healthy controls using Sequenom MassArray (518 RA cases on both platforms). Immunochip data for the FCGR locus from 3870 RA cases and 8430 healthy controls were combined with the FCGR plex data. Results: Resequencing 21 kb of FCGR2A and its promoter confirmed 61 SNPs and identified 5 novel markers. Locus-specific genotyping combined with data from the Immunochip project were used to fine map the original association in FCGR2A. Combined analysis of locus specific and Immunochip data identified two groups of associated SNPs stratified by minor allele frequency, all confined to a single interval flanked by two recombination hotspots. Two potential causative nonsynonymous coding SNPs, which alter the affinity of the receptor for ligand, were in linkage disequilibrium with the index SNPs. A haplotype of these two risk markers showed strongest association with disease (P ¼ 0.0003, OR 1.17; 95% CI 1.07, 1.27). Conclusions: We identified an additional independent genetic risk factor at the FCGR2A locus in RA. The functional impact of these variants and potential pathogenic role for FCGR2A in RA will be presented with respect to the dual role of FcRIIa in innate and adaptive immunity. Disclosures: The authors have declared no conflicts of interest. Background: In 2009 we instigated an evidence-based standardized care pathway for the treatment of newly-diagnosed RA. The 18 month pathway is based on set treatment regimens and reviews by rheumatologists, specialist nurses and therapists. Patients are divided into three cohorts: mild disease in which patients have low disease activity and are treated with non-steroidal anti-inflammatory drugs; moderate disease which meets the entry criteria for the ARC Low Dose Glucocorticoid Study [1] and is treated initially with low dose MTX (7.5 mg weekly) plus prednisolone 7.5 mg daily; and severe disease where patients meet the entry criteria for the COBRA study [2] and are treated initially with a COBRA regime. Treatment can then be varied as needed. In this audit of outcome we aimed to compare the response of patients to that in the original trials [1, 2] and record the occurrence of adverse drug reactions (ADRs) and medication changes. Methods: Of 157 pathway patients 19 sets of notes were not available leaving 138 notes which were scrutinized for diagnosis date, treatment cohort, review dates, DAS, HAQ scores, cumulative adverse drug reactions (ADRs) and cumulative medication increases. A standardized data collection sheet was used and descriptive statistics derived. Results: One patient was classified as mild and not included further, 101 as moderate and 36 as severe. Outcomes are shown in Table 1 . We compared our moderate cohort outcome with those reported in published trials: 21% of our cohort was in remission at 22 weeks which was not significantly different from AMBITION (12.1%), but was significantly less than the CALDERA trial (36%) at 24 weeks. In our COBRA cohort 64% of patients achieved a DAS < 3.5 at 1 year, which was not significantly different than the 71% achieved in the BeSt trial. Conclusions: Our more severe patients treated with COBRA improved more and more quickly than moderate patients treated with low-dose combination therapy but had more ADRs. Many patients required an increase in medication, which was facilitated by frequent review but suggests there may be scope to improve the regime. Overall, our pathway produced results comparable to those achieved in some trials. The BSR/BOA guidelines emphasise the importance of early aspiration in the management of an acute hot swollen joint. An acute hot joint service was developed in Gateshead to address delays in joint aspiration. Patients with a history of trauma or hip pain were excluded. It was hoped that by streamlining the patient pathway, admissions and length of stay would be reduced as previously acute hot joints were managed as an acute admission and delays of more than 12 h before joint aspiration were not uncommon. Methods: The service was configured to ensure triage with high priority from accident and emergency (AandE) followed by referral to rheumatology between 9 am and 5 pm and to orthopaedics out with normal working hours. Patients who were systemically well with a temperature of <388C, who had no contraindications to outpatient management were seen either in ambulatory care or clinic on the same or next day. All other patients were admitted to medical admissions unit (MAU) for assessment. GP referrals were triaged by phone. During September and October 2012 an audit proforma was completed for all referrals to the hot joint service. In addition to demographics and clinical information we collected details on synovial fluid analysis.
FINE MAPPING THE FCGR2A ASSOCIATION WITH SUSCEPTIBILITY TO RHEUMATOID ARTHRITIS
HEALTH SERVICES RESEARCH, ECONOMICS AND OUTCOMES RESEARCH
Results: 29 patients were referred. 23 (79%) referrals were received between 9 am and 5 pm, Monday to Friday. 28/29 patients were seen on the same day. 1 patient with non infective olecranon bursitis was seen the following day. AandE referred the most-15 (52%), with the remainder coming from primary care 6 (28%), 1 from the helpline and 7 inpatient referrals (2 of which were on MAU). Following review of the 22 patients referred from the community 36% required admission and we were able to discharge 14 (64%) home. 4 were admitted to exclude sepsis (2 were confirmed-infected olecranon bursitis-staph aureus and a cellulitis), 3 were admitted for pain control or poor mobility and the final patient was found to have a non rheumatological problem. The average length of stay for the patients admitted was 3.6 days. Only 1 patient was pyrexial at the time of initial review. The median time overall from referral to aspiration was 60 min (average 172 min). The commonest inflamed joint was the knee (48%) followed by the wrist (21%) and the elbow (10%). The most common final diagnosis was crystal arthritis-9 (31%). No patients with septic arthritis presented during the study period.
Conclusions:
The referrals to the service were appropriate and long delays prior to aspiration were abolished. The majority of patients referred from the community could be managed successfully as outpatients. There was a lower than expected incidence of septic arthritis suggesting this may have been overestimated in previous case series. We have shown that a specialist streamlined pathway for patients with acute hot joints reduces the time to diagnosis, reduces admissions and in turn reduces the pressure on MAUs and in patient beds.
Disclosures:
The authors have declared no conflicts of interest. Background: Rheumatology is an under-resourced specialty in many countries and thus waiting lists are among the longest in the medical profession. Non-attendance at outpatient clinics remains a challenge to the health service resulting in valuable appointments going unused. The failure to attend rate has been running at 20% for several years for our service. On July 7th 2011 an SMS text reminder system prior to patient clinic date was put in place at Rheumatology Department, Merlin Park/Galway University Hospitals to improve clinic attendance. Aim: 1) To evaluate whether the SMS text reminder reduced the non-attendance rate in our outpatient clinic; 2) To identify the reasons for non-attendance after introduction of SMS text reminder system. Methods: An anonymous Questionnaire was posted to all patients failed to attend Rheumatology out-patient clinic from 7 July 2011 till 31 December 2011 at our University Hospital asking them to indicate reason/s for non-attendance. A self-addressed pre-stamped envelope was also included for reply. A follow-up telephone inquiry was made to those who didn't respond to the postal Questionnaire. The study was approved by our local audit and ethics committee. All data were entered in XL sheets for analysis purpose. Results: 498 patients (18.9%) didn't show up at clinic. A total of 407 (81.7%) responded, 330 postal and 77 telephone. Almost half of all respondents claimed to have neither received the appointment letter (24%) or the SMS text reminder (23%), with 11% getting neither. 21% patients were unwell to attend clinic and about 29% did not write their diagnosis. Conclusions: Nearly 1 in 5 patients fail to attend rheumatology appointments at our university hospitals. The most common reason cited was a lack of notification. The addition of an SMS text reminder had very little impact on the attendance rate. Background: Patients with acute, hot swollen joint/s usually present to the accident and emergency department. The British Society for Rheumatology (BSR) has set out clear guidelines on the management of the acute hot swollen joint including recommendations for early joint aspiration and specialist referral of all patients with suspected septic arthritis. We therefore investigated whether the management of patients with acute hot swollen joint/s at St Mary's Hospital (SMH) Accident and Emergency (AandE) adheres to the BSR guidelines. Methods: Patients who attended the SMH AandE department with acute hot, swollen joint/s over a 12 month period from Apr 2011 to Apr 2012 were identified by searching the SMH database using key words like: septic arthritis; joint effusion; tenosynovitis; and gout. Their medical notes, pathology and microbiology results, and discharge summaries were examined. Patients with clinical features consistent with an alternative diagnosis were excluded. Data were collected regarding the occurrence of joint aspiration, collection of blood cultures, antibiotic treatment, analgesia, and specialist referral. Results: A total of 39 patients were included. In all, 20/39 (51%) patients had a joint aspiration performed with: 13/20 (65%) by orthopaedic surgeons; 4/20 (20%) by emergency physicians; and 3/ 20 (15%) by rheumatologists. All 5 prosthetic joints were referred to and managed by orthopaedic surgeons. In 13/19 (68%) patients the decision not to aspirate was not in accord with the BSR guidelines. The reason for not aspirating was clearly documented in 14/19 (73.7%) of cases. The most common reason was a low clinical probability of septic arthritis as assessed by the specialist (12/19, 63%), followed by 5/19 (26%) cases based on not elevated inflammatory markers. Inflammatory markers were measured in 35/39 (89.7%) patients. Blood cultures, however, were obtained in only 9/20 (45%) patients which yielded a positive result in 1 (5%) patient. A total of 12/39 (30.7%) patients were treated with antibiotics the choice of which was in accord with local policy in 9/12 (75%) patients. Of those with joint aspirates, 7/20 (35%) patients had received antibiotics, and in all (100%), this was after the aspiration. Average time to antibiotics was 3.9 h. Analgesia was given to 36/39 (92.3%) of patient within 37 min of registering. Conclusions: Our data indicated that despite clear guidance from the BSR on the management of acute hot swollen joint, adherence in clinical practice is not optimal. Consequently, we have designed a local AandE pathway adapted from the BSR guideline to be included in the induction programme for new staff. Several factors such as lack of awareness among junior doctors and insufficient experience in aspirating joints, may potentially explain the noted deviation from the BSR guidance. Disclosures: The authors have declared no conflicts of interest.
AN AUDIT OF MISSED RHEUMATOLOGY OUTPATIENT APPOINTMENTS
WASTE NOT, WANT NOT: IS ANTI-TNF WASTAGE PREVENTABLE?
Carolyn Bell Background: Anti-TNF therapy (aTNF) has revolutionized rheumatology but also made it an expensive specialty. Humira, enbrel and infliximab are independently within the top 10 selling pharmaceutical products 2012 with combined sales of $2.9 billion. In today's NHS financial accountability is imperative and includes minimizing drug waste. As injectable aTNF is delivered directly to patients home any unused stock is wasted. We aimed to quantify injectable aTNF waste, reasons for it and explore options for reduction. Methods: Patients return unused injectable aTNF to the department. Patient hospital number, volume of drug and date are recorded on an Excel database. Returns between Oct 2011 and Oct 2012 were identified and patients' clinical letters reviewed to establish the timing, reason and a clinical decision made as to the predictability of drug discontinuation. Pharmacy provided drug costs. A questionnaire was completed by clinical staff (7 Consultants, 3 SpRs and 3 CNS) regarding clinical scenarios of primary/secondary failure and significant events requiring aTNF cessation. It explored knowledge of the process of stopping aTNF including its delivery. Results: 390 patients received injectable aTNF and 25 stopped (4 inefficacy, 12 side effects, 6 new contraindication, 3 other); 2 were deemed predictable (see Table 1 ). Analysis of the questionnaire identified several themes. Firstly, reluctance to stop aTNF in suboptimal efficacy; secondly sources of delay in stopping drug delivery with varied methods of communication to CNS staff (email/ letter/direct) and uncertainty of the process of halting aTNF delivery. It revealed reliance on CNS staff to unite clinical decisions with prescription management. Conclusions: Unused aTNF amounted to £35 500 representing 1.4% of our £2.5 million annual biologics spend. Whilst only a small proportion, when dealing with large figures small percentages amount to considerable sums. Wastage was largely unpredictable; simply recognizing patients expected to stop is unlikely to be beneficial. The questionnaire identified sources of unnecessary drug delivery due to delays in stopping aTNF. Staff needs education and a streamlined pathway for aTNF cessation instituted. Currently deliveries are made quarterly; reducing this interval may minimize waste without extra cost, but an increased workload preparing and dispensing prescriptions is inevitable. To uncouple any dissociation between decision making and prescribing flagging prescription requests prior to assessment points (e.g. 6 months in RA) would ensure criteria are fulfilled and appropriate prescribing. We have identified local actions to reduce aTNF wastage. Our experience is unlikely to be unique and thus represents an area for considerable potential saving nationally. Background: Biologics prescribing costs are spiralling upwards as many patients remain on medication for many years. Long-term safety concerns are diminishing but the effects of decades of use are unknown. Optimal dosing, treatment duration, and effects of reducing medication for patients in or near remission are unclear. This abstract details one consultant's experience of reducing biologic doses in patients with RA, PsA and AS for those with very low disease activity. Methods: Patients with RA, AS or PsA on biologic medication with low disease activity or in remission for at least 6 to 12 months were identified during routine clinic appointments between May 2011 and October 2012. Patients were offered a biologic dose reduction on condition that they could resume their previous dose in the event of a relapse. Etanercept dose was reduced to between 10 and 25 mg weekly, infliximab from 3 mg per kg to 2.5 mg per kg, adalimumab from 40 mg fortnightly to 40 mg 3 weekly. DAS was subsequently monitored every 3 months and previous doses were resumed in the event of a flare-up. Results: Of 52 patients with RA on biologic medication, 13 patients, all in remission (DAS28 <2.6, mean DAS28 2.1) had their dose of biologic medication reduced: 7/13 male, 6 female, average age 65 years, average disease duration 8 years. 1 patient stopped each of adalimumab and rituximab completely. 10/13 patients remained in remission (mean DAS28 2.5) after an average follow-up duration of 13 months. 3/10 who remained in remission were on their second biologic medication after primary failure of their first. 3/13 patients relapsed at between 3 and 5 months and were re-started on their previous dose with a rapid return to previous DAS28 scores. Out of 10 patients with AS on biologic medication, 5 with very low DAS (mean BASDAI 0.6, pain VAS scores 0.6) had their dose of biologic reduced. I patient on each of etanercept and adalimumab stopped their biologic completely. All still had low DASs at an average follow-up duration of 8 months (BASDAI 0.5, pain VAS 0.3). 2 patients with PsA out of 6 on biologics successfully reduced their dose with no worsening of disease activity after 9 months of follow-up. In 2012 the proportion of patients seen as new referrals was relatively constant (mean 20%; range across RU, 16-26%) and had not changed significantly since 2008. In 2012 the proportion of patients discharged varied from 12-31% (7-26% in 2008) with an unchanged mean of 17%. As noted in 2008 only 1 RU discharged more patients than they saw as new referrals in 2012. The mean ratio of follow up:new (FU:N) patients seen increased from 3.4 to 4.0 from 2008 to 2012. FU:N ratios continued to vary widely across the region in 2012 with a range across RU of 2.9-5.1. There remained a significant variation across the region with regard to the case mix of patients seen. The mean proportion of patients seen for each diagnostic category in 2012 was: inflammatory arthritis 51%; connective tissue disease 14%; spinal pain (SP) 10%; OA 5%; soft tissue problems 4%; metabolic bone disease 4%; fibromyalgia 3%; crystal arthritis 2%. A further 7% of patients had an uncertain/other/unstated diagnosis. Overall these proportions had changed little from 2008 to 2012 with the variation between RU also remaining relatively stable. The mean proportion of patients seen for SP remained stable at 3% in 2008 and 2012 for 6 of the RU and was 25% in 2012 and 27% in 2008 for the other 2 RU. The 2 RU seeing a high proportion of patients with SP had the lowest FU:N ratios. RU with specialist interests attracted a higher proportion of new referrals for their clinical interest than the regional average. The requested time interval to the next appointment varied from 1 to 104 weeks. Across the RU the range of median and mode requested time intervals to next appointment was 14. I felt welcomed by the nurse?
The amount of room in clinic was satisfactory?
What was the quality of verbal information given?
What was the quality of written information given?
The appointment was helpful? My questions were answered satisfactorily? I feel confident to start my medication?
Answers were scored using a likert scale with a maximum score of 5 meaning very satisfied. Results: In 3 months 90 patients were seen in clinic. An average of 2 h and 40 min per week was saved by counselling patients in groups. The average wait from referral to appointment was 10 days however some patients took longer than this because of abnormal tests or personal issues such as holidays. Levels of patient satisfaction were very high with average scores ranging from 4.6 to 5 out of 5 across the 7 questions in the group clinic and from 4.8 to 5 in the individual clinic. There was minimal variation between the scores given by the 2 groups with the largest on the question of whether they felt confident to start the medication. Here the individual clinic gave an average score of 4.8 with the group clinic giving an average score of 4.6. Conclusions: Group DMARD clinics allow us to keep up with demand for clinic slots while freeing up our nurses to undertake other duties. Patient satisfaction remains very high in the group clinic although we must be sure to address all of our patient's ideas, concerns and expectations with regards to taking the new drug. Disclosures: The authors have declared no conflicts of interest. Background: European guidelines have proposed that joint protection and hand exercise should be used in the management of hand OA. However, the evidence regarding the cost-effectiveness of these interventions has not been well established. A 2x2 factorial trial was carried out to compare the effectiveness of joint protection (JP), hand exercise (HE), joint protection plus hand exercise and leaflet and advice (LA). The trial demonstrated JP was the most effective option as indicated by the primary outcome measure (OARSI/OMERACT responder criteria), at 6 month follow-up. The primary aim of this study is to assess the cost-effectiveness of management options for hand OA. In addition, given the absence of consensus regarding the conduct of economic evaluation alongside factorial trials, we compare different analytic methodologies. Methods: A cost-utility analysis was undertaken over a 12 month period. Patient level resource use and EQ-5D data were obtained from postal questionnaires, and mean costs and quality-adjusted life years (QALYs) were calculated for each trial arm. Incremental costeffectiveness ratios (ICERs) were estimated and cost-effectiveness acceptability curves constructed. The base case analysis used a within the table analysis methodology, which involves comparing LA, JP plus HE, JP alone and HE alone. Two further methods were explored: the at-the-margins approach, and a regression-based approach with or without an interaction term. Results: 257 patients were randomized to receive one of the interventions. Mean costs (S.D.) recorded in each treatment arm were £50.24 (265.40) for LA, £104.40 (93.28) for JP plus HE, £82.29 (108.22) for JP and £57.21 (76.88) for HE. Mean QALYs (S.D.) associated with each trial arm were 0.662 (0.166) for LA, 0.658 (0.164) for JP plus HE, 0.659 (0.157) for JP and 0.681 (0.135) for HE. In the base case analysis, hand exercise was the most cost effective option with an ICER of £367 per QALY gained compared with leaflet and advice, and with an 80% chance of being cost-effective at a threshold of £30,000 per QALY gained. With the alternative analysis methods, HE remained the most cost-effective management strategy, with ICERs consistently less than £2,000 per QALY gained. Conclusions: The results of this study showed that HE was the most cost-effective option irrespective of the adopted methodology. These findings should be viewed in the context of both management options being very inexpensive and the associated clinical findings that indicated joint protection was the most effective option at 6 months. Possible reasons for this disparity include the use of different outcome measures (responder criteria vs QALYs), measurement at different time points (6 months for the primary clinical outcome vs 12 months for the economic analysis), reduced statistical power and more generally, the distinct paradigmatic objectives of clinical and economic evaluation. Disclosures: The authors have declared no conflicts of interest. There is a growing body of evidence that shows treatment of RA should be started as early as possible to minimize damage to joints and prevent long-term disability. For optimal outcomes, the clinical consensus is that treatment with biologic therapies should commence within 3 months of symptom onset. Our objective is to highlight the need for a review of the eligibility criteria for use of biologic therapies to treat RA in the UK, and to illustrate the number of patients with RA who would be eligible to receive biologic therapies if the criteria of DAS28 !3.2 were to be applied.
COST-EFFECTIVENESS OF JOINT PROTECTION AND HAND EXERCISE FOR HAND OSTEOARTHRITIS
BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS
Methods:
The UK-population estimate (n ¼ 62,262,000) was applied to the NICE costing template for biologics for RA, and the number of RA patients eligible to receive biologic treatment was calculated. Prevalence rates were based on Symmons et al. [1] Percentages have been reworked by reference to the population age and sex profile. Based on the Commissioning Guide for biologic therapies, which incorporates estimates of patients with a DAS28 !5.1 in whom treatment with DMARDs has failed; 10% patients with RA are eligible for treatment with biologics. Based on clinical opinion collected from a number of leading UK rheumatologists the proportion of patients eligible for treatment with biologics at a DAS28 score !3.2 was estimated to be approximately 50%. Results: The total estimated prevalence of patients with RA is 421,022. Utilizing the restrictions outlined in current guidance and applying a DAS28 score !5.1 results in 42 102 RA patients being eligible to receive treatment with biologics. Whereas 210 511 patients would be treated if a DAS28 score !3.2 were to be applied. Conclusions: Restrictions on UK HTA guidance leave a significant number of patients untreated compared with international clinical guidance. There is widespread agreement that there is a need to make these drugs available to those patients most likely to respond to them. Disclosures: M.L., Bristol-Myers Squibb-Employee. C.R., BristolMyers Squibb-Employee. S.S., Bristol-Myers Squibb-Employee. (15) years, disease duration: 20 (19) months) were randomized to receive either Usual Care (n ¼ 52) or the EXTRA programme (n ¼ 56). 4 supervised sessions (1 h each) were delivered 2/week for 2 weeks (n ¼ 4-6/group). Upper limb disability (Disabilities of Arm, Shoulder, and Hand questionnaire), grip strength, function (Grip Ability Test), and disease activity (28 Joint Disease Activity Score) were assessed at baseline, 3 months (primary end point) and 9 months. Analysis was conducted using Analysis of Variance (treatment, time, and treatmentxtime interaction). Significance was accepted at P < 0.05. Results: Compared with a Usual Care control group, participants who completed the EXTRA programme demonstrated improved disability, function, and non-dominant grip strength, with no adverse effects on disease activity (Table 1) (LoS) is one of the main drivers of costs for orthopaedic surgery in RA and it is anticipated that better medical and surgical treatments of recent years should result in shorter stays. Some data on LoS trends have been reported in RA-related orthopaedic interventions, but less is known about associated clinical factors. In the current economic climate, with over-pressurized health services, identifying and targeting such factors could result in reduced LoS, and improved health care utilization planning.
A BRIEF EXERCISE AND SELF-MANAGEMENT PROGRAMME IMPROVES UPPER LIMB DISABILITY IN PEOPLE WITH EARLY RHEUMATOID ARTHRITIS
Methods: LoS has been examined in two very similar multi-centre inception cohorts, the Early RA Study (ERAS) (n ¼ 1465, 1986-1999) and the Early RA Network (ERAN) (n ¼ 1236, 2002-2010) . Details of orthopaedic interventions included date, type of procedure and LoS, obtained from clinical and national datasets (National Joint Registry and Hospital Episode Statistics). Follow-up was based on the National Death Register. Standard clinical, laboratory and X-ray measures recorded at baseline and annually were used to investigate factors affecting LoS with univariate and multivariate regression analysis. Results: A total of 1602 procedures were performed in 770 (29%) of 2701 patients in ERAS and ERAN. 40% were major, of which 88% were total joint replacements (mainly knee then hip), 24% intermediate (mainly hand/foot surgery) and 16% minor (soft tissue surgery). A gradual reduction in the median LoS was noted over 25 years for all procedures: 10, 4 and 2 days respectively (IQRs 7-15, 3-7, 1-4) in ERAS and 7, 3 and 1 days (IQRs 5-8, 1-7, 1-2) in ERAN. The improvement in median LOS over time and in comparison with national data for the commonest types of surgery will be displayed graphically. Extrapolation of national data suggests that in the 1990s TKRs resulted in longer LoS than in the 2000s. The cost of a TKR based on 5 days LoS currently in the UK is £5576, and the decline in LoS across most procedures has resulted in reduced costs. In multivariate analyses LoS varied significantly by type of procedure, DAS28, haemoglobin (HB) levels and HAQ scores. Normal baseline HB significantly reduced LoS by 1.8 days (P ¼ 0.001), baseline HAQ < 1 by 1.8 days (P ¼ 0.002) and low 1 year DAS28 (<3.2) by 1.1 days (P ¼ 0.051). Conclusions: LoS in RA-related orthopaedic surgery has declined over the last 25 years, which could be a reflection of improved management of RA, and better medical and surgical in patient treatments. Normal baseline HB, low baseline HAQ and low DAS28 at 1 year were found to be significant predictors for reduced LoS. Disclosures: The authors have declared no conflicts of interest. Background: An estimated 600,000 RA sufferers in UK are taking long-term DMARDs with MTX the commonest DMARDs used. In England, there were 137 patient safety incidents during the last 10 years involving MTX including 25 patient deaths and 26 cases of serious harm. At Queen Alexandra Hospital, Portsmouth, we have 6 patients taking MTX admitted with neutropenia sepsis in the last 2 years. All 6 patients at were poorly compliant with monitoring ranging from 3 to 9 months. Regular blood tests are mandatory to monitor patients on immunosuppressants ensuring patient safety. The current shared care monitoring model between specialists and GPs is unable to identify patients that are non-compliant to monitoring. Our recent clinical audit has shown only 76% compliance with blood tests Results: 16 patients were males and 9 were females, minimum age was 30 years and maximum age was 75 years, mean age was 54.28 years. Mean duration since the procedure was carried out was 49.08 months (minimum 22 months and maximum 93 months). All patients had inflammatory arthritis. Single joints were injected in 18 patients and multiple joints injected in 6 (only knee and ankle joints were injected). 10 patients (40%) were very satisfied with the procedure, 7 (28%) quite satisfied, 6 (24%) quite disappointed and 2 (8%) were very disappointed. 18 patients stated they were willing to have the procedure done again if needed and 7 were not willing. The majority of patients did not experience skin burns, worsening of pain or any other problems as a result of the procedure. The majority of patients (68%) experienced improvement in the pain after the procedure with the effect lasting for 14.16 months on an average. The majority of patients did not need a repeat procedure (88%) and only a minority needed repeat procedure (12%). 24 patients (96%) did not have joint replacement since the procedure and 1 (4%) needed joint replacement. Background: Prescribing of anti-rheumatic and immunosuppressive drugs in men with active rheumatic disease trying to conceive is required to control disease activity and thus increase the chance of successful conception. This area of prescribing however is complicated by concerns regarding the safety of many of these drugs. These concerns arise from safety information based mainly on experimental and animal studies. Human data are limited to inadvertent exposure described in case reports/series and population registries. Previous systematic reviews have identified a risk of oligospermia with SSZ and gonadal toxicity with cyclophosphamide in men trying to conceive, as well as theoretical concerns for LEF and biologics. Therefore, we have undertaken a systematic review to update information on this subject. Methods: A systematic search of PubMed and Embase was carried out using relevant keywords for pregnancy, men, conception and drugs commonly prescribed in patients with rheumatic disease from 1966 onwards. The drug categories included analgesics, disease modifying anti-rheumatic drugs, biologics and steroids. Review articles and non-English language papers were excluded. Results: Fifteen studies were selected for detailed review, describing relevant drug use in men with rheumatic disease, IBD, posttransplantation, psoriasis, multiple sclerosis and leukaemia. The studies consisted of 2 case reports, 6 case series, 4 cohort studies and 3 case-controlled studies, of which only 4 had a comparator control group. These studies identified 2015 drug exposures (705 NSAIDs,514 steroids,368 AZA,164 ciclosporine,111 MTX,59 SSZ,46 etanercept,16 infliximab,13 HCQ,11 rituximab,6 adalimumab,2 LEF) in 1743 men trying to conceive, leading to 1778 pregnancies. There were limited reports of the effects upon fertility (in 133 men) and one retrospective questionnaire study of 30 men taking AZA reported an increased rate of infertility (>1 year to conception) of 15.2% vs 8.3% of controls. The confounding effects however, of underlying (Crohn's) disease and the possibility of female infertility, were a limitation of this study. Of the 1706 live births, 32 congenital malformations were reported which were not specific to any drug. In the remaining 72 pregnancies which miscarried the precise number of elective terminations was not stated in all studies. Conclusions: This systematic review did not find an increased risk of adverse pregnancy outcomes in partners of men taking antirheumatic, immunosuppressive and biologic drugs whilst trying to conceive. Although the small numbers of patients taking newer antirheumatic and biologic therapies mean there remains insufficient evidence to advocate the safe use of these drugs. This information however, is useful when counselling men of potential risk particularly after accidental conception. Disclosures: The authors have declared no conflicts of interest. Background: GCA is the most common form of systemic vasculitis in the UK with presenting features including headache, scalp tenderness, jaw claudication and visual loss. Aortic involvement can also be present in patients with GCA. This study investigated the predictors of aortic aneurysm (AA) in patients with GCA. Methods: A 20 year longitudinal study of GCA subjects was conducted from 01/01/1991 to 31/12/2010. From the General Practice Research Database (GPRD), 6999 patients with GCA were identified using Read codes. All GCA subjects were aged 40 or above at the time of diagnosis. Aortic aneurysms were defined by Read codes in the GPRD, and ICD10 and OPCS codes were used in linked Hospital Episodic Statistics (HES) data. Variables assessed included age, BMI, gender, smoking status and alcohol consumption, prior medical conditions including a previous history of hyperlipidaemia, hypertension, diabetes, cardiovascular disease, cerebrovascular disease, peripheral vascular disease and previous prescriptions for antihypertensives, lipid lowering and diabetic medications. Subjects were observed from the date of GCA diagnosis to the earliest of date of death, transfer out (left the study), end of study date or date of aortic aneurysm diagnosis. Sub-hazard ratios (sHR) were derived from a survival model with death as the competing risk adjusting for potential confounders. We used multiple imputation to account for missing values of BMI (25%), smoking status (10%) and alcohol status (19%). Results: The mean (S.D.) age at GCA diagnosis was 71.9 (10.7) years, BMI was 26.6 (5.3) kg/m 2 , 28.8% were male, 43.3% were ex/current smokers and 65% consumed alcohol. The median (IQR) follow-up was 4.1 (1.6-7.7) years and the median age at aortic aneurysm was 75.5 (69.5-80.9) years. At the time of GCA diagnosis, 5.2% had a previous history of hyperlipidaemia, 28.7% had hypertension, 9.8% had diabetes, 9.6% had cardiovascular disease, 9.0% had cerebrovascular disease, 2.8% had peripheral vascular disease, 15.6% had received lipid lowering medication and 41.0% had received antihypertensives. The independent predictors of AA during follow-up, associated with an increased risk, were male gender (sHR 2.1 (95% CI 1.4, 3.2), ex-smokers (sHR 2.2 (95% CI 1.2, 4.0), current smokers (sHR 3.8 (95% CI 2.2, 6.5), and prior prescriptions for anti-hypertensives (sHR 1.6 (95% CI 1.0, 2.6). A previous history of diabetes (sHR 0.2 (95% CI 0.1, 0.8) was associated with a lower risk of aortic aneurysm. Conclusions: This large UK GPRD cohort study of patients with GCA demonstrates an increased risk of developing an aortic aneurysm in patients who are male and have a history of smoking. In the general population, diabetes has been shown to have a protective effect against aortic aneurysm. This is the first study to demonstrate this association in patients with GCA. Disclosures: The authors have declared no conflicts of interest. Background: Autonomic nervous system (ANS) involvement has been studied in both RA and AS but with conflicting results and varying degrees of involvement. However Sudoscan a simple, non-invasive device for quick and quantitative assessment of sudomotor function, which has recently become available (Impeto Medical Device, Paris, France) and has not yet been employed for assessment of sudomotor function in RA and AS. Sudomotor function has also never been correlated with cardiovascular autonomic neuropathy (CAN). We aimed to investigate in RA and AS: (i) ANS functions utilizing both traditional CAN and using the novel sophisticated Sudoscan; (ii) relationship between the sudomotor function and indicators of CAN. Methods: 15 patients with RA, mean (S.D.) age 41.87 (11.80), 15 patients with AS, mean (S.D.) age 32.27 (10.98), and 15 age-matched control subjects were selected from healthy clinic staff with mean (S.D.) age 32.93 (1.62) years. The peripheral sympathetic autonomic function was assessed by Sudoscan through measurement of electrochemical skin conductance (ESC). CAN responses were assessed by the four standard cardiovascular reflex tests. Sympathetic dysfunction was examined by applying: blood pressure (BP) response to standing and BP response handgrip test. Parasympathetic dysfunction was examined by applying: heart rate (HR) response to deep breathing and HR response to standing. Results: 60% patients with RA and AS had both parasympathetic and sympathetic CAN dysfunction. 60% (n ¼ 9) RA patients and 33% (n ¼ 5) AS patients had peripheral sympathetic autonomic dysfunction. None of the healthy volunteers had abnormal ANS dysfunction. Patients with RA and AS had significantly higher HR response to standing (P ¼ 0.04), BP response to handgrip (P ¼ 0.01) and Sudoscan (P ¼ 0.002) when compared with healthy controls. Lower ESC was associated with higher number of abnormal CAN results, and patients with ESC < 60 mS were approximately 2.5 times likely to have one or more abnormal CAN response compared with patients with ESC > 60 mS. Sudomotor function significantly correlated with HR response to standing (P < 0.05) and BP response to handgrip (P < 0.05) but not with BP response to standing. Significant correlation was found between HR response to deep breath and sudomotor function in RA but not in AS. Background: Prescribing of anti-rheumatic and immunosuppressive drugs in pregnant women with active autoimmune rheumatic disease (ARD) is complicated by safety concerns. These concerns arise from safety information based mainly on experimental and animal studies. Human data are limited to inadvertent exposure described in case reports/series and population registries. Previous systematic reviews have identified risks with various anti-rheumatic drugs and theoretical concerns for LEF and biologics. This systematic review updates information on this subject. Methods: A systematic search of PubMed and Embase was carried out using relevant keywords for pregnancy, lactation, SLE, antiphospholipid syndrome (APS), Sjö gren's Syndrome (SS) and Scleroderma (SSc) and drugs commonly prescribed in patients with rheumatic disease from 1966 onwards. Non-English language papers were excluded. Results: The search strategy identified 124 papers, describing relevant drug use in pregnant women with SLE, APS, SS and SSc. These studies identified over 5850 drug exposures during pregnancy to: anti-hypertensives; endothelin receptor antagonists; aspirin; non-steroidals; bisphosphonates; heparin; warfarin; anti-rheumatics; antimalarials; immunosuppressives; intravenous immunoglobulin; plasmapheresis and steroids. Multiple case-reports/series/controlled studies reported increased congenital malformations following exposure to angiotensin converting enzyme inhibitors (ACEI).Two systematic reviews of HCQ found no increased risk of miscarriage, prematurity or congenital defects and showed reduced SLE disease activity during pregnancy. Miscarriages and congenital malformation were frequently observed in a small number of pregnancies exposed to MMF (n ¼ 16), MTX (MTX, n ¼ 11) and CYC (n ¼ 9). Of 10 patients treated with abatacept there were 4 spontaneous and 2 elective miscarriages, although 8 of these patients had concomitant MTX (n ¼ 7) or LEF (n ¼ 1) therapy. From 31 additional reports of antiTNFalpha exposure in pregnant patients with ARD since a 2008 update, there were 24 live births with one congenital abnormality as well as 5 spontaneous and 2 elective miscarriages. No other consistent adverse pregnancy outcomes were observed with the other drugs reviewed. Conclusions: This systematic review highlighted the safety of HCQ in pregnancy and its beneficial effects upon lupus disease activity. It also confirmed an increased risk of adverse pregnancy outcomes in patients taking ACEI, MTX, MMF and CYC therapy. The small numbers of pregnancies exposed to biologic therapies mean there remains insufficient evidence to advocate the safe use of these drugs. This information however, is useful when counselling women of potential risk before treatment and particularly after accidental conception whilst taking these therapies. Disclosures: The authors have declared no conflicts of interest.
MAKE IT HAPPEN, IMPLEMENTING A DMARDS MONITORING SERVICE REDESIGN
PREDICTORS OF AORTIC ANEURYSMS FOR GIANT CELL ARTERITIS SUBJECTS
THE PHENOTYPIC CONSEQUENCES OF MUTATIONS IN
MUSCLE DISORDERS
SYSTEMATIC INVESTIGATION OF MOLECULAR MIMICRY CANDIDATES IN IDIOPATHIC INFLAMMATORY MYOPATHIES IDENTIFIES POTENTIAL NOVEL AUTOANTIGENS
Stephen P. Background: The idiopathic inflammatory myopathies (IIM) are autoimmune disorders characterized by acquired proximal muscle weakness and inflammatory cell infiltrates in muscle biopsies. The aetiology of IIM is largely unknown but is likely to be caused by environmental risk factors in genetically predisposed individuals. An estimated 80% of adult IIM cases have myositis-specific autoantibodies or antibodies against a novel or unidentified autoantigen. Several infectious agents have been reported to cause a primary inflammatory response of the musculature; homology between human and pathogen derived peptides may facilitate activation of T cells which are cross reactive to self-antigens (known as molecular mimicry). We hypothesized that autoantibodies are directed against antigens in IIM due to recognition of linear sequence epitopes from non-human proteins. Methods: 13 viruses, 3 bacteria and 1 parasitic protozoan previously associated with myositis were identified from the published literature. Systematic in silico comparison of non-human proteomes to the human proteome was carried out using an adaptation of a molecular mimicry pipeline to identify homologous linear sequences, using BLASTp and an overlapping sliding window of 14 amino acids (14-mer). For each proteome, after removal of conserved proteins, we recorded the number of 14-mer molecular mimicry candidates, the number of unique proteins these mapped to, and the most significant 14-mer BLASTp e-value. Shannon Entropy scores were recorded for each mimicry candidate as a measure of sequence complexity to eliminate repeat sequences. Result significance was assessed by 1000 permutations of randomly shuffled protein sequence, whilst maintaining the amino acid composition. Results: A number of notable molecular mimicry candidates were identified (permuted P ¼ 0.001) including a 134 amino acid region of Epstein Barr Virus IL-10 aligned to human IL-10; this homology has been previously reported in SLE, providing proof of principle; Human Immunodeficiency Virus Gag-Pol polyprotein aligned to CCHC-type zinc finger, nucleic acid binding protein (CNBP); and Toxoplasma gondii zinc finger (C3HC4 type) protein aligned to Tripartite motifcontaining protein 60 (TRIM60). These results are supported by previously identified functions or structural motifs of known myositis autoantigens. Several human proteins, including bile salt export pump and sperm associated antigen 5, also showed homology to multiple bacterial or viral species. Conclusions: We have identified a number of potential signatures of molecular mimicry in IIM which may indicate novel autoantigens. This provides a rationale for experimental investigation of autoantibodies against these proteins in individuals with IIM as a fruitful area for future research. This approach is broadly applicable and may potentially elucidate etiological mechanisms in other autoimmune disorders. Disclosures: The authors have declared no conflicts of interest. Background: The primary outcome measure recommended by regulatory agencies for structure modifying drugs in OA is a reduction in joint space narrowing (JSN) over 3 years. While JSN is an established feature of knee OA on X-ray, its relationship with knee replacement (TKR) is not well understood. This study evaluated 5-year change of joint space and the future risk of a TKR over a 15 year follow-up. Methods: A nested case control study was performed using the Chingford Women's Cohort, a UK population-based study with a twenty-year follow-up. At the knee level, 40 TKRs (cases) were observed between year 5 and year 20 visits (of which 10 were bilateral). Cases and controls (1:10 ratio) were matched by baseline age (within 3 years), side of TKR and time. Subjects had to have baseline and year 5 X-rays, and not to have a TKR over this period. Digitized X-rays were read for minimum quantitative joint space width (mJSW) (using the KneeMorf software program) as well as categorical joint space narrowing (cJSN) using a standard atlas (grade 0 [normal] through grade 3 [bone-on-bone]). Reproducibility for mJSW was calculated using intra-class correlations (ICC) on 50 X-rays read by two readers. Reproducibility has previously been reported to be good for catJSN and Kellgren and Lawrence (K/L) grade (ICC >0.7). 5-year change was calculated as an increase of one or more grades for cJSN or K/L and as any change of joint space for mJSW (widening and narrowing). Multivariable conditional logistic regression was used to analyse risk of TKR in relation to change in JSN and K/L grade. Results: The ICC's for inter-observer reproducibility for medial mJSW were 0.96 (95% CI 0.93, 0.98) and 0.81 (95% CI 0.69, 0.89) for mJSW in the lateral compartment. Cases (n ¼ 40 knees) had higher mean BMI (27.0 vs 25.3, P ¼ 0.05) and more knee pain at year 5 (54.3% vs 16.7%, P < 0.001) compared with controls (n ¼ 383). The mean mJSW at baseline was 4.2 mm (1.2 S.D.) for cases and 4.4 mm (0.8 S.D.) for controls. Over 5 years, 20% of cases and 7% of controls showed medial cJSN narrowing, while 52% of cases and 53% of controls showed any medial mJSW narrowing. 5-year change in cJSN was significantly associated with TKR in both the medial [OR 3.32 Background: Poor physical performance (PP) is associated with disability, lower quality of life and higher mortality rates. Knee and hip OA can both cause joint pain and restrict range of movement. In this study we examined relationships between hip and knee OA defined by self-report or clinical American College of Rheumatology (ACR) criteria and PP, before and after adjustment for pain scores, in a cohort representing 6 European countries. Methods: The European project on OA (EPOSA) study comprises 2942 men and women aged 65-85 years from the Netherlands, Germany, Sweden, Spain, Italy and the UK. Participants completed a questionnaire detailing self-reported OA, demographics, lifestyle and WOMAC. Clinical OA was defined based on ACR criteria. PP was determined from assessments of walking speed, chair rises and balance (tandem stand) to create a composition score (0-12); low PP was defined as 9. Results: The mean (S.D.) age of the study population was 74.2 (5.1) years. Advanced age, female gender, lower educational attainment, abstinence from alcohol, and higher BMI were independently associated with low PP. Having clinical knee OA, hip OA, or both were associated with a higher risk of low PP; OR (95% CI) 2.93 (2.36, 3.64), 3.79 (2.49, 5.76), and 7.22 (3.63, 14.38) respectively, with relationships robust to adjustment for the confounders above and WOMAC pain score. Self-reported OA was also associated with low PP, but relationships were attenuated after adjustment for confounders, and relationships were not observed at the knee in Sweden. Low PP was associated with low self-reported WOMAC physical function score (P < 0.001). Conclusions: OA at the hip, knee, or both are associated with low PP, and relationships are robust to adjustment for pain for a clinical diagnosis. This is important as an individual with low PP is more likely to report poor physical function. Disclosures: The authors have declared no conflicts of interest. 
RETROSPECTIVE ANALYSIS OF THE OUTCOME OF PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS
Lucia
SELF-REPORTED AND CLINICAL HAND OSTEOARTHRITIS ARE ASSOCIATED WITH LOW GRIP STRENGTH INDEPENDENT OF PAIN ACROSS SIX COUNTRIES: THE EUROPEAN PROJECT ON OSTEOARTHRITIS
Background:
The relationship between a radiological diagnosis of knee OA and symptoms of knee pain has been often debated by rheumatologists. Here we report the relationship between baseline grading for knee OA according to Kellgren and Lawrence (K and L) scoring and a clinical diagnosis of knee OA according to American College of Rheumatology (ACR) criteria some 9 years later in a cohort of older UK adults. Methods: The study population was taken from the Hertfordshire Cohort Study, who were born in Hertfordshire between 1931 and 1939. This study included 987 people, who were aged 59.9-71.5 years at the time knee radiographs were taken during the period 1999-2002. Weight-bearing AP radiographs were taken of both knees, and graded for severity of OA according to KandL grade to assess tibiofemoral (TF) OA, and lateral semiflexed knee radiographs used to assess patellofemoral (PF) OA. Follow-up was performed in 2011 when participants completed a questionnaire detailing self-reported OA, demographic and lifestyle information and WOMAC. Clinical OA was defined based on ACR criteria. Subjects who underwent knee arthroplasty during follow-up were excluded from the analysis. A total of 424 participants completed the study. Results: Sixty-five (15.3%) subjects had a clinical diagnosis of OA at follow-up, while 259 subjects (61.1%) had knee OA radiographs graded as K and L score of 0 or 1 at baseline. K and L grading at baseline was strongly associated with a clinical diagnosis of OA at follow-up (P < 0.0001); similar relationships were seen between individual component of radiographic OA at the TFJ (presence of osteophytes; joint space narrowing) and a clinical diagnosis of OA at follow-up but were not statistically significant when assessing relationships between PFJ space narrowing and clinical OA at follow-up. Relationships between radiographic OA and a self-reported diagnosis of OA were very similar. Background: Although joint pathology makes an important contribution to OA pain, the precise relationship between pain and structural pathology is not entirely clear. Imaging studies have indicated possible associations between pain and synovitis, subchondral changes or osteophytosis, but associations with histopathology have not been explored in detail. We aimed to identify histopathological features that are associated with symptomatic human knee OA as a first stage towards identifying specific molecular and cellular changes that may contribute to OA knee pain. Methods: Medial tibial plateaux and synovium were obtained from patients undergoing total knee replacement (TKR) for OA and postmortem (PM) cases who had not sought help for knee pain. Firstly, 26 consecutive TKR cases (TKR1) were compared with 26 aged-matched PM controls (PM1), to determine which histological features were associated with end-stage OA. Secondly, 21 TKR cases (TKR2) were compared with 21 PM cases (PM2) with similar total macroscopic chondropathy, to indicate which structural features are associated with symptomatic OA, assuming TKR2 experienced greater levels of knee pain than PM2. OA changes and synovial inflammation were histologically graded. Results: Total knee replacement cases (TKR1 [median age 61 years, 31% male]) displayed more severe (each P < 0.05) cartilage surface changes, tidemark breaching, proteoglycan loss, synovitis and subchondral bone marrow replacement by fibrovascular tissue than post-mortem controls (PM1 [median age 61 years, 62% male]). A second group of total knee replacement cases (TKR2 [median age 71 years, 62% male]) and post-mortem cases (PM2 [median age 73 years, 48% male]) displayed similar macroscopic chondropathy scores (207 v. 193 , respectively, P < 0.05). In univariate analyses, severity of cartilage surface changes, synovitis and subchondral bone marrow replacement by fibrovascular tissue were significantly greater in TKR2 than PM2 cases. Synovitis and cartilage changes remained significant after using logistic regression to adjust for macroscopic chondropathy (P < 0.05). Conclusions: Synovitis, tidemark breaching, subchondral bone marrow replacement, loss of proteoglycans and cartilage surface integrity are associated with end-stage OA, although most of these features are also found in some PM cases who have not sought TKR. Symptomatic OA is associated with greater synovitis and loss of cartilage surface integrity, than in PM cases with similar macroscopic joint surface appearances who did not seek TKR. Synovitis may be a key structural feature associated with symptoms in OA, which is consistent with previous data obtained from MRI studies. Further research is being undertaken to determine specific inflammatory mechanisms in OA that may be associated with pain, and to develop targeted treatment strategies for the relief of OA pain associated with synovitis. Disclosures: The authors have declared no conflicts of interest. Background: The role of the trabecular bone in OA is not yet well understood but MRI-detected bone marrow lesions (BMLs) are associated with pain and progression of OA. Few studies have assessed the histology of BMLs; one showed increased trabecular spacing and decreased trabecular numbers using micro CT. Normal trabecular architecture is crucial to the load-bearing function of the subchondral bone. This study was to assess the histology of BMLs in 8 people with OA, in particular to describe the trabecular structure and architecture. Methods: 8 patients underwent MR imaging prior to hip arthroplasty. Femoral heads were immobilized in a plastic frame and MR-imaged within 24 h of surgery. Fixed external markers such as the fovea capitis ensured calculation of an exact angle for the plane of section including the BML. The femoral head was sectioned with a bandsaw and embedded in methyl methacrylate; 10 and 300mm slices were taken with a microtome. A previously reported and validated technique, initially developed for osteoporosis, was used, which allows direct measurement of trabecular bone interconnection by measuring the trabecular termini within 300mm slices. This technique was applied to areas with and without BMLs using an overlying slide marked with a 1 cm 2 grid. Slices were also assessed for vascularity (vessel count), cysts and fibrosis. Results: The areas corresponding to BML showed trabecular architecture disruption; trabecular interconnection was markedly lower in the BML area compared with the non-BML area (median termini count 3.4/cm 2 vs 1.2/cm 2 , P ¼ 0.03). BML areas showed higher vascularity (median number of 5 vessels/cm 2 ) compared with 2/cm 2 in the non-BML area. Descriptively, the BML areas demonstrated multiple areas of cystic change containing adipose cells and fibrous tissue, often surrounded by thickened trabeculae,. There was evidence of increased bone formation around the cysts as demonstrated by an osteoid border of unmineralized bone. Marked osteopoenic areas as shown by fragmented trabeculae were also noted within the BML area, usually adjacent to cystic change. Marrow fibrosis and oedematous adipocytes were common, in agreement with previous studies Conclusions: The results confirmed that OA BMLs demonstrate marked changes within the subchondral trabecular bone, with osteopoenic areas and increased osteoid tissue. Although the sample size is small, for the first time an increase in the vascularity of BML areas has been demonstrated. A novel direct measure of the trabecular connectivity noted increased trabecular disconnection, which will alter the load-bearing function of the subchondral bone. Alendronate has been shown to preserve normal trabecular interconnection, as assessed by this histological method. Recent work shows that bisphosphonate may reduce BML progression and pain in OA; our study suggests this may be due to the preservation of normal trabecular structure within BMLs. Disclosures: The authors have declared no conflicts of interest. Background: This report presents a follow up study conducted in continuance to an original double blind, prospective study which assessed the effectiveness of a foot-worn biomechanical device and treatment (AposTherapy). The biomechanical device comprises four individually calibrated elements attached onto foot-worn platforms and enables unloading of the diseased articular surface and simultaneously train neuromuscular control by controlled perturbations. The purpose of this study was to examine the long-term effectiveness of this biomechanical treatment in reducing pain and improving function in patients with knee OA. Methods: 35 patients with knee OA volunteered to continue the follow-up for additional 24 months. 26 of them were in the active group and 9 patients were in the control group. Patients continued the treatment with the device that had been individually calibrated to accommodate a diminished-pain joint alignment and train neuromuscular control. Patients were assessed 12 months and 24 months after the original study ended. Primary outcome measures were the WOMAC index and the Aggregated Locomotor Function (ALF) assessment. Secondary outcome measures were the SF-36 health survey and the Knee Society Score. Results: At 12 and 24 months, the active group maintained the significant pain relief and improved function that were obtained at the end of the original study, showing a decrease of 3.6 cm and 3.5 cm, in the WOMAC-Pain subcategory, representing a mean improvement of 68% and 66%, after 12 and 24 months respectively (P < 0.001). Patients also showed a decrease of 3.5 cm and 3.3 cm, in the WOMAC-function subcategory, representing a mean improvement of 69% and 65%, after 12 and 24 months respectively (P < 0.001). Patients maintained the improved ALF score after 12 and 24 months showing a decrease of 13.9 sec and 12.9 sec, representing a mean improvement of 37% and 34%, after 12 and 24 months respectively (P < 0.001).
MAGNETIC RESONANCE IMAGING AND HISTOLOGICAL ASSESSMENT OF BONE MARROW LESIONS IN THE OSTEOARTHRITIC HIP
OSTEOARTHRITIS: TREATMANT 261. A 2-YEAR FOLLOW-UP STUDY ON THE EFFECT OF A FOOT-WORN BIOMECHANICAL DEVICE AND TREATMENT FOR REDUCED PAIN AND IMPROVED FUNCTION IN PATIENTS WITH KNEE OSTEOARTHRITIS
Conclusions:
The reduced pain and improved function following treatment with the biomechanical device was maintained after 12 and 24 months indicating that this therapy might be an effective, long term treatment for patients with knee OA. Disclosures: The authors have declared no conflicts of interest. Background: Physical therapy and biomechanical interventions for patients with hip OA should aim to reduce pain, improve function and restore or maintain gait patterns close to normal. The purpose of this study was to evaluate the effect of a biomechanical therapy on the pain, function, quality of life and spatio-temporal gait patterns of patients with hip OA. Methods: 60 patients with hip OA were examined before and after 12 weeks of using the biomechanical device and treatment (AposTherapy). Patients were evaluated using the WOMAC questionnaire for pain and function and the SF-36 Health Survey for quality of life. Patients also underwent a computerized gait test. Results: After 12 weeks of treatment, a significant improvement was found in the patients' velocity, step length and cadence (P 0.001). WOMAC-pain, WOMAC-stiffness and WOMAC-function subscales were significantly improved compared with baseline (P 0.001). SF-36 physical score subscale improved significantly (P ¼ 0.007), whereas the SF-36 mental subscale improved but did not reach the statistical significance threshold. Conclusions: Patients with bilateral hip OA treated with the examined therapy for 12 weeks showed statistically and clinically significant improvements in pain, function and gait patterns. These findings suggest that this treatment may be an additional useful tool for conservatively treating patients with hip OA. Further RCT studies are needed to evaluate the effect of the examined therapy on hip OA population. Disclosures: A.E., Apos-Share Holder. A.M., Apos-Share Holder. G.S., Apos-Employee. All other authors have declared no conflicts of interest. 2013, 10.30-11.30 POSTER VIEWING III has shown that Sequentially Programmed Magnetic Field (SPMF) therapy is effective in ameliorating the signs and symptoms of OA, and inducing regenerative activity in the chondrocytes by an increase in the cartilage thickness. The objective of this study was to evaluate the efficacy of SPMF therapy on a larger group of patients with confirmed knee OA. This study was conducted on patients with varying grades of OA, using the American Knee Society rating system. Methods: 1000 patients with clinically confirmed knee OA were recruited for the follow up study to evaluate the efficacy of SPMF therapy. Patients were exposed to SPMF for 1 h for 21 consecutive days. The dosage was calculated depending on the grade of OA and the amount of subchondral bone involved. The SPMF therapy was delivered to the target area by a computer controlled device, which generates the Sequentially Programmed Magnetic Field, by specially designed Magnetic Field Generators (MFGs). SPMF therapy is based on the principle that exposure to SPMF can recreate the piezoelectric stimuli, which enhances mitosis and cell regeneration by normalizing the aberrant electromagnetic fields of micro tubules forming the centrioles. All subjects were evaluated with Total Knee Score (TKS) and Total Functional Score (TFS); pre treatment, post treatment at 21days and at 3 months.
A NON-INVASIVE FOOT-WORN BIOMECHANICAL DEVICE AND TREATMENT FOR PATIENTS WITH HIP OSTEOARTHRITIS
Michael
SEQUENTIALLY PROGRAMMED MAGNETIC FIELD
Results: This study showed statistically significant improvement in TKS and TFS in all the patients, who were able to walk comfortably for considerable distances at the end of the treatment and this improvement persisted when they were re-evaluated at 3 months. The TbRIIÁk-fib mouse model of SSc, in which TGFb signalling is upregulated in fibroblasts, is susceptible to fibrotic lung injury whereas the TbRII-null-fib strain, in which TbRII is conditionally knocked out in fibroblasts, is resistant to bleomycin-induced lung fibrosis. We have used an illumina microarray platform to profile lung or skin fibroblasts from these two strains and identified a cohort of genes that determine susceptibility or resistance to experimental lung fibrosis, comparing with a control group using whole lung from TbRIIÁk-fib animals and wild type littermates (n ¼ 3) on the same microarray platform. Technical validation of data and additional quantitation of gene and protein expression was performed with replicate samples.
Results: Functional classification of the TbRIIÁk-fib lung fibroblast gene expression signature includes key genes that are implicated as pathogenic drivers of fibrosis and inflammation and potential biomarkers in SSc. Conversely, many of these genes are downregulated in TbRII-null-fib mice, including BMP4 (fold reduction in TbRII-null-fib 31.8, P < 0.02; fold upregulation in TbRIIÁk-fib compared with WT 2.01, P < 0.6); elastin (TbRII-null-fib 17.8, P < 0.14; TbRIIÁk-fib 1.86, P < 0.09); CCL2 (TbRII-null-fib 56.8, P < 0.09; TbRIIÁk-fib 1.72, P < 0.03) and MMP13 (TbRII-null-fib 13.2, P < 0.08; TbRIIÁk-fib 3.6, P < 0.4). CTGF (CCN2) was strongly upregulated in TbRIIÁk-fib lung fibroblasts, but showed less downregulation than other genes in the TbRII-null-fib, probably reflecting multiple pathways of activation. No signature of overexpression of these genes was present in the whole lung analysis suggesting that fibroblast-specific differences in gene expression determine altered fibrotic response. Conclusions: These data define a cohort of genes differentially expressed in fibroblasts that associate strongly with susceptibility or resistance to experimental lung fibrosis. These transcripts include many that are important in tissue repair and that have previously been shown to be over expressed in SSc skin samples. They suggest that resident fibroblast gene expression signature may govern fibrosis in lung and skin. Disclosures: The authors have declared no conflicts of interest. Background: Gastrointestinal tract (GI) and cardiac disease (CD) are important complications of systemic sclerosis (SSc). In this study we ask whether patients with severe GI tract SSc have increased frequency of cardiac complications during their disease course. Methods: 168 SSc patients with prominent GI symptoms were identified from the research database of a major tertiary referral centre using key words: malnutrition, pseudo-obstruction and enteral or total parenteral nutrition (TPN). Severe GI disease was defined as those presenting with at least 3 episodes of pseudoobstruction requiring hospital admission or nutritional support, malabsorption syndrome or diarrhoea and weight loss (without malnutrition) responding to antibiotics. Cases that had developed CD at any point in their disease course were collated. Manifestations of significant CD (excluding pulmonary arterial hypertension) included arrhythmia, conduction block, pericardial effusion, cardiac failure, ischaemic heart disease or myocardial abnormality on cardiac MRI. Results: 31 patients (18.4%) were identified with severe GI disease and CD. There were 16 females. 55% of cases had diffuse cutaneous SSc (3 myositis overlap, 1 SLE overlap). Median age at presentation of CD was 52 (n ¼ 21) range 36-81. Median time from diagnosis of SSc to onset of CD was 60 months (n ¼ 22) (range 5-256). Severe GI disease occurred in 26-61% of cases. Small bowel thickening or dilated small bowel loops including pneumotosis cystoides of the colon were demonstrated on CT in 23% of patients. 26% of patients required nutritional support (5 TPN, 3 percutaneous endoscopic gastrostomy or percutaneous enterojejunal insertion), Surgical intervention including decompression was necessary in a minority (16%). Of this cohort of patients, 35% developed significant atrial tachycardias requiring antiarrythmics. Two patients had episodes of non-sustained VT. In one, this was associated with low potassium and magnesium. One patient had a cardiac arrest on developing renal crisis. 19% developed significant conduction blocks (5 requiring permanent pacemaker), 23% had severe left ventricular dysfunction, 19% myocardial infarction and 6% required emergency pericardiocentesis for large pericardial effusions. Two patients had evidence of myocardial fibrosis on cardiac MRI. Two developed restrictive cardiomyopathy and 1 restrictive myocarditis. Conclusions: We described a cohort of patients with severe GI disease who developed significant CD. The majority of these were arrhythmias and in some, electrolyte imbalance was a major contributory factor. The potential association of severe cardiac and GI disease in SSc is important for management and may indicate a shared pathogenic mechanism. Disclosures: The authors have declared no conflicts of interest. Background: Calcium deposits (calcinosis) in systemic sclerosis (SSc) are clinically heterogeneous both for site and severity of involvement. Despite often leading to complications such as digital ulcers and driving poor hand function, little attention has been paid to the pathogenesis of calcinosis and the therapeutic options remain limited. The presence of calcinosis in limited cutaneous SSc as well as in the diffuse form suggests that the condition may be associated with vasculopathy rather than fibrosis, however to date, no formal studies have addressed this hypothesis. We performed video-capillaroscopy of peri-calcinotic skin and unaffected skin in the same but contra-lateral region of interest (ROI), to determine whether we could detect any calcinosis-specific change in the capillaroscopic pattern. Methods: Eighteen calcinotic deposits and contra-lateral ROIs were analysed with an Optilia Digital video-capillaroscopy system equipped with 200x magnification lens. For each calcinotic deposit we captured images in the 4 surrounding quadrants within 3 millimetres of the lesion. Images from each quadrant were captured, identified and stored and in an electronic database. Analysis of the images was performed by two rheumatologists fully trained in video-capillaroscopy and blinded to the clinical details. Presence of enlarged capillaries, giant capillaries, haemorrhages, drop-out, disorganization and capillary ramifications were assessed independently. McNemars tests were employed for statistical analysis. Results: Twelve of the 18 calcinotic deposits were located at the distal phalanx, 3 at the proximal phalanx, 1 at both the middle and proximal phalanx and two at the palmer metacarpal. Drop out areas were observed in at least 1 quadrant of all 18 calcinotic deposits vs 7 contra-lateral control ROIs (P ¼ 0.05). Enlarged capillaries were observed at 17 deposits vs 11 ROIs (P ¼ 0.05), giant capillaries, disorganization and capillary ramifications were observed at 7, 9 and 5 deposits, respectively, while none were observed in any ROIs (P < 0.05 for all). Haemorrhages were observed at 5 deposits and 2 ROIs, (P ¼ 0.05). Conclusions: This pilot study suggests that specific features of severe vasculopathy such as drop out areas, giant capillaries and disorganization of the vascular array are observable in plain skin videocapillaroscopy and may be specifically associated with calcinotic deposits in SSc. Further studies are warranted both to unravel the role of vasculopathy in the pathogenesis of calcinosis and to determine potential benefit of therapeutic options targeting peripheral vasculopathy. Disclosures: L.L., Actelion-Travel Grant. All other authors have declared no conflicts of interest. Background: Clinical trials in systemic sclerosis (SSc)-associated hand ischaemia are hampered by inadequate outcome measures. We evaluated the utility of near-infrared spectroscopy (NIRS) to measure regional oxygen saturation (RSO 2 ) and laser Doppler flowmetry (LDF) to measure perfusion in digits. Methods: 25 patients with SSc (including 11 who required treatment with iloprost for hand ischaemia) and 25 healthy controls (HC) were recruited. All SSc and HC subjects were invited for 3 visits: 2 trial protocol visits (conducted in a temperature-controlled room at 228C, following !12 h abstention from vasodilator drugs, caffeine or alcohol) and one outpatient protocol visit (conducted in standard air-conditioned room, with no preparation). Patients receiving iloprost (SScI) had a further trial protocol visit after 4 days of the infusion. At each visit, RSO 2 was measured in the left middle/ring finger for 5 min, as LDF was assessed over the same period from the right middle/ring finger. The utility of LDF and NIRS as monitoring tools were assessed by comparing medians and IQR between HC and SSc, dynamic range, coefficient of variation, reproducibility of measurements between trial visits (T1 and T2), correlation of measurements between the trial visits (Tav) and the Outpatient visits, and by the ability of the measurements to detect change after iloprost infusion. Results: The mean (range) ages of participants was HC 43y (22-84), SSc 59y (21-83), SScI 61y (46-77). No trends suggestive of variation of LDF or RSO 2 with age were seen in HC or SSc, so all data were included in analysis. Although the RSO 2 was not significantly different between all SSc and HC, the subset 12 SScI receiving iloprost had lower RSO 2 and this approached significance compared with HC (P ¼ 0.07). Conclusions: LDF exhibits a greater dynamic range than NIRS and a significant difference can be seen between SSc patients and HC. However, the variance and reproducibility of NIRS is superior and this technique can detect a significant improvement following iloprost infusion. NIRS may be a valuable tool for monitoring hand ischaemia longitudinally in patients, either in clinical trials or in clinics. Disclosures: The authors have declared no conflicts of interest. Background: High magnification nailfold videocapillaroscopy (NVC) is currently the 'gold standard' for identifying nailfold capillary abnormalities suggestive of a systemic sclerosis (SSc) spectrum disorder, but is not widely available to all clinicians. The dermatoscope (magnification in the order of x10) is a small, inexpensive and easily portable piece of equipment, with good intra-and inter-observer reliability in identifying capillary abnormalities suggestive of a connective tissue disease. We investigated the ability of individuals with an interest in SSc and general rheumatologists to classify nailfold capillary images obtained by NVC and dermoscopy, and compared the two techniques. We set out to test the hypothesis that graders were more likely to be able to grade capillaries by NVC (because of better visualization) and that more capillaries would be graded abnormal by NVC. Methods: NVC and dermoscopy images were acquired from 32 subjects (10 nailbeds, 320 sets of images) with a spectrum of nailfold capillary characteristics (normal to grossly abnormal). A secure webbased interface was constructed. Individuals with an interest in SSc (identified through clinician SSc networks) and consultant rheumatologists in the north west of England were invited to participate. Each rater was randomly assigned the images from a subset of 4 subjects i.e. 4 (subjects) X 10 (fingers) þ 5 (random hand repeated) ¼ 45 images for each technique. Images were assessed on a 0-3 ordinal scale of severity of abnormality: normal, mildly abnormal, definitely abnormal, grossly abnormal and rating 4 unable to classify. The rater could not return to previous images. Only the results for ability to classify (rating 4) are presented here.
SEVERE GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS IS FREQUENTLY ASSOCIATED WITH HAEMODYNAMICALLY SIGNIFICANT CARDIAC INVOLVEMENT
VIDEO-CAPILLAROSCOPY ASSESSMENT OF PERI-CALCINOTIC SKIN INDICATES SPECIFIC FEATURES OF SEVERE VASCULOPATHY ASSOCIATED WITH CALCIUM DEPOSITS IN SYSTEMIC SCLEROSIS
A COMPARISON OF NEAR-INFRARED SPECTROSCOPY AND LASER DOPPLER FLOWMETRY AS TOOLS FOR ASSESSING SEVERITY OF HAND ISCHAEMIA IN SYSTEMIC SCLEROSIS
A WEB-BASED STUDY COMPARING VIDEOCAPILLAROSCOPY AND DERMOSCOPY IN THE ASSESSMENT OF NAILFOLD CAPILLARIES IN PATIENTS WITH SYSTEMIC-SCLEROSIS SPECTRUM DISORDERS
Michael
Results: 48 raters from 12 countries participated in the study (26 specialists, 22 general) with 1920 paired ratings for each technique. Capillary images were gradable by both NVC and dermoscopy in 1289 (67.1%) of instances, alone by NVC in 360 (18.8%), by dermoscopy alone in 105 (5.5%) and by neither in 166 (8.7%). The ability to grade images against clinician subgroup, by image type is presented in Table 1 .
Conclusions: Most images could be graded by NVC and dermoscopy (but more by NVC). No difference was seen between the specialist and general rheumatologists in the ability to grade NVC images, but specialists were slightly more likely to grade dermoscopy images. Further work is warranted to validate dermoscopy in the assessment of patients with SSc-spectrum disorders. Disclosures: The authors have declared no conflicts of interest. Background: Digital ulcers (DUs) are frequent and persistent clinical manifestations of systemic sclerosis (SSc). They occur in up to 30% of all patients with SSc and cause considerable disability. Previous analyses of the multinational DUO Registry have shown that the number of DUs in patients with SSc negatively impacts work and daily activities. As UK-specific data on work and daily activity impairment are relevant for the management of DU disease in the UK, this subanalysis investigated the impact of DUs in UK patients enrolled in the DUO Registry. Methods: The DUO Registry is a European, multicentre, prospective, observational cohort study of SSc patients with a history of DU disease. A functional impairment questionnaire was completed by patients upon enrolment into the DUO Registry. This questionnaire included three topics: work impairment (factoring work time missed, work time attended, and % of subjective impairment while at work), daily activity impairment (%), paid and unpaid help (hours), all with regard to the past month. In this analysis, patients were stratified according to number of DUs at enrolment (0 DU, 1-2 DUs, !3 DUs). Results: From April 2008 to May 2012, 323 patients from the UK were enrolled in the registry. 311 patients (96.2%) completed at least one part of the questionnaire. Of the 311 patients, 82.6% were female. 47 (15.1%) had no DUs, 179 (57.6%) had 1-2 DUs, and 85 (27.3%) had !3 DUs. The mean age at enrolment was similar across the groups (53.9, 53.6, and 52.3 years, respectively). Work impairment was Background: IL6 is a key mediator recently implicated in activation of extracellular matrix (ECM) proteins in scleroderma (SSc) fibroblasts. CCL2 is a proinflammatory chemokine that is overexpressed in diffuse cutaneous systemic sclerosis (dcSSc). We explored interaction between these two major mediators that may be critical in the recruitment of inflammatory cells into lesional skin and whether this may affect fibroblast ECM production. Methods: Dermal fibroblasts were cultured from skin biopsies from healthy controls (n ¼ 4) and early stage dcSSc (n ¼ 4). Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples of the latter group. Expression of CCL2 and IL6 were assessed using immunohistochemistry with specific markers CD3, CD68 and CD14 on PBMCs. IL6 activation of CCL2 and the ability of SSc fibroblast derived CCL2 to induce PBMCs migration through an endothelial layer was studied in vitro using Transwell migration assays, and the effect of the PBMCs-fibroblast interaction on production of ECM proteins, asmooth muscle actin (aSMA) and Collagen type-I (Col-I) was measured using neutralizing antibodies against CCL2 and IL6 ligand-receptor axis. Results: Stimulation of normal and SSc dermal fibroblasts with recombinant human IL6/sIL-6R led to a dose dependent increase of the CCL2 (mean AE S.E.M. % basal expression) with IL6 25 ng/ml and sIL-6R 20 ng/ml at 48 hours, inducing the production of the maximum concentration of CCL2 (91 AE 4%). IL6 trans-signalling increased migration of PBMCs (n ¼ 3) up to (31 AE 3.5 % P < 0.05) in normal fibroblasts and (44 AE 2.3 % P < 0.02) in SSc fibroblasts. The migration of PBMCs was abrogated by the addition of neutralizing antibodies against CCL2 and IL6 ligands by (18 AE 6.3 % P < 0.04) and (13 AE 8.2% P < 0.04) respectively in the presence of control fibroblasts and (25 AE 5.1 % P < 0.03) and (18 AE 5.4% P < 0.04) respectively with SSc fibroblasts. IL6 trans-signalling significantly increased CCL2 expression (33 AE 2.7% P < 0.03 and 45 AE 5.6% P < 0.04) in control and SSc fibroblasts respectively. This was more prominent in SSc fibroblasts and reduced in the presence of anti-IL6R and/or anti-CCL2 antibodies in both control and SSc fibroblasts. Markers for monocytes CD68, and T cells CD3 confirmed localization of CCL2 to monocytes but no expression of IL-6 ligand was confirmed.CCL2 induced migration of PBMCs the production of ECM proteins at 24 h in the presence of PBMCs with increased levels of aSMA (53 AE 5.9%, P < 0.05) and Col-I (22 AE 3.6%, P < 0.03) compared with SSc fibroblasts. Conclusions: Our results suggest that PBMCs are recruited via fibroblast-derived CCL2. The recruited PBMCs further activate ECM synthesis from SSc fibroblasts and have a particularly strong effect on the production of aSMA. These data suggest interplay between fibroblast-mononuclear cells may mediate the fibrotic response and that the CCL2/IL6 axis represents a potential therapeutic target for fibrosis in SSc. Disclosures: C.D., Actelion, Roche-Consultation Fees. V.O., Roche-Research Support. All other authors have declared no conflicts of interest. Background: Although significant female gender predominance is seen in majority of large systemic sclerosis (SSc) cohorts, studies have suggested that male gender associates with more severe disease and worse outcome. We explore disease characteristics in male and female patients with SSc from a single centre cohort.
ORGAN-BASED COMPLICATIONS AND SURVIVAL IN MALE AND FEMALE PATIENTS WITH SYSTEMIC SCLEROSIS
Methods: We analysed a cohort of incident cases of SSc that developed between 1995 and 1999 and were followed up for up to 15 years.
Results: A total of 398 SSc patients were included. Of those 54 (14%) were male. Mean age at onset was 49 years in male and 48 years in female patients. A higher proportion of men had diffuse cutaneous (dc) subset of SSc compared with women-48% (n ¼ 26) v 35% (n ¼ 120), but the difference was not significant. Duration of Raynaud's phenomenon (RP) with relation to onset of first non-RP symptom of SSc was significantly shorter in male patients with mean (range) of 30 (-12 to 339) months compared with 81 (-29 to 744) months in females (P ¼ 0.003).
Comparison between frequencies of autoantibodies demonstrated significant differences only in anti-centromere antibody (ACA) positivity, which was twice as common among women-30% (n ¼ 96) compared with 15% (n ¼ 8) in men (P ¼ 0.022). At disease onset a larger proportion of men were current (24%) or past (44%) smokers compared with 14% and 25% respectively among women, P ¼ 0.001. There was a significantly higher proportion of male patients with some degree of pulmonary fibrosis (PF) confirmed on HRCT compared with females-74% (n ¼ 39) v 50% (n ¼ 169), P ¼ 0.001. Cumulative incidence of clinically significant (cs)PF over the entire follow-up period was 55% in male and 28% in female patients (P ¼ 0.002), being 33% and 44% in men and 22% and 27% in women at 5 and 10 years of follow-up. We found no significant association between smoking history and development of csPF. There were no differences in incidence of pulmonary hypertension (PH), cardiac involvement or scleroderma renal crisis (SRC) between genders. At 5 years 6% of men and 4% of women had developed PH, 2% of men and 3% of womencardiac SSc and 2% of men and 6% of women-SRC while at 10 years PH was found in 16% of men and 13% of women, SRC in 4% of men and 7% of women and there were no new cases of cardiac SSc in either group.
There was no significant difference in survival between genders with 91% of both male and female patients being alive at 5 years. Over the entire follow-up survival was 56% in males and 66% in females. In comparison, the expected survival of the general population with matched age was 99.7% at 5 years and 96.5% at 15 years for women and 98.1% and 92.6% respectively for men. Conclusions: Although male patients have significantly higher incidence of csPF, reflected by the lower frequency of ACA and show a trend towards greater frequency of diffuse SSc subset compared with females, there was no significant increase in overall mortality. Disclosures: The authors have declared no conflicts of interest. Background: Systemic sclerosis (SSc) is a rare disease characterized by autoimmunity, fibrosis and vasculopathy. P2Y1 is a transmembrane G-protein coupled receptor found in the basal layer of the epidermis, involved in controlling proliferation of keratinocytes. P2X7 is an ATP receptor cation channel, involved in terminal differentiation of keratinocytes in the stratum corneum. These receptors play an important role in inflammation and immunity. Epidermal injury induces ATP release and P2X7 signal transduction amplifies the local innate response. We have previously found altered terminal differentiation in the epidermis in SSc patients. We hypothesized that ATP-P2X7 signalling amplifies innate responses in the epidermis in patients with SSc, possibly leading to the development of downstream fibrosis and autoimmunity. Methods: We sampled the epidermis of 6 patients with diffuse cutaneous SSc, and 6 healthy controls using a dermal suction blister method. Using immunohistochemistry we stained for P2X7 (Caltag Labs) and P2Y1 (Abcam). In total 5 high power fields from each of 6 SSc and 6 control individuals were studied. The results were analysed using Chi-Squared tests. Dermal blister fluid samples (healthy control n ¼ 9, diffuse SSc n ¼ 12) were profiled by Luminex array for inflammatory cytokines, chemokines, and growth factors. Results: The distribution of P2Y1 was uniform throughout the epidermis in 6/6 healthy controls and 6/6 patients. P2X7 was found in 6/6 healthy controls in the terminally differentiated cornified layer of the epidermis. 0/6 SSc patients showed this normal terminal differentiation pattern (P < 0.001 Chi Squared). One third of the patients showed focally induced over expression of the P2X7 receptor throughout the epidermis, compared with none of the control samples. The remaining two-thirds of patients showed decreased expression of P2X7 in the cornified layer of the epidermis. This was found to be not significant on Chi-Squared test. Luminex array profiling of the dermal blister fluid suggested increased inflammatory cytokines (mean IL-8 in SSc 527 pg/ml vs 147 pg/ml in controls, mean IL-1beta in SSc 3.7 pg/ ml vs 2.4 pg/ml), and growth factors (HGF 247 pg/ml SSc, 112 pg/ml controls P < 0.02, and VEGF-A 208 pg/ml in SSc, 87 pg/ml in controls). Conclusions: The expression of P2X7 receptors were found in an abnormal density across the epidermis of patients with SSc compared with healthy controls. This was not the case with the P2Y1 receptor which is important in the proliferation and differentiation of keratinocytes within the epidermis. Our data show that there is altered terminal differentiation within the stratum corneum of patients with diffuse SSc. The expression of P2X7 receptors in defined foci and altered cytokine profile, indicate active inflammation in the epidermis which provides an insight into the pathogenesis of SSc and the role of the epidermis and its transdifferentiation. Disclosures: The authors have declared no conflicts of interest. Background: We explore incidence and predictors of pulmonary fibrosis (PF) and pulmonary hypertension (PH) in patients with systemic sclerosis (SSc). Methods: We analysed incident cases of SSc that developed over 5 years and were followed up for up to 15 years. Clinically significant (cs) PF was defined as the presence of fibrosis on high-resolution CT with either forced vital capacity (FVC) or carbon monoxide diffusing capacity (DLCO) 55% or a 15% decline from baseline in FVC or DLCO. PH was confirmed by right heart catheter with mean pulmonary arterial pressure of !25 mmHg; cases with elevated pulmonary capillary wedge pressure were excluded. Results: 146 diffuse cutaneous (dc) SSc and 252 limited cutaneous (lc) SSc cases were included. During the entire follow-up, 48% of the dcSSc and 24% of the lcSSc patients developed csPF (P < 0.001). Approximately half of the subjects developed csPF within the first 3 years of disease (23% of dcSSc and 11% of lcSSc). The earliest cases of PH were diagnosed within the first 3 years from SSc onset. Five and 10 year incidence of PH was 4% and 13% for dcSSc and 5% and 15% for lcSSc patients, P ¼ 0.558.
ALTERED EXPRESSION OF P2X7 RECEPTOR IN THE EPIDERMIS OF DIFFUSE SCLERODERMA PATIENTS
INCIDENCE AND PREDICTORS OF PULMONARY COMPLICATIONS IN SYSTEMIC SCLEROSIS
Significant predictors of pulmonary complications from univariable and multivariable Cox proportional hazards analysis are summarized in Table 1 . The variables that remained significant independent predictors of csPF in a multivariable analysis were subset, FVC, DLCO, anti-Scl 70 antibodies and anti-centromere antibodies (ACA).
i158 Thursday 25 April 2013, 10.30-11.30 POSTER VIEWING III /l, white cell count 1.3 x 10 9 /l, neutrophil 0.1 x 10 9 /l); chest radiograph showed basal shadowing; CT of the chest and abdomen showed appearances suggestive of pancolitis and left lower lobe consolidation; with negative stool, urine, blood, sputum, ophthalmic culture including HIV serology. CMV colitis was considered with gancyclovir 5 mg/kg 12 hourly and filgrastrim (GCSF) 3000 mg s/c daily commenced immediately after specialist consultation. Unfortunately, patient deteriorated clinically with multiple episodes of per rectal bleeding despite ongoing resuscitation and invasive haemodynamic monitoring, needing surgical intervention (total colectomy with end ileostomy). Further blood investigations showed a CMV viral load of 1.95 x 10 8 (LOG 8.29) copies per ml. Stool analysis showed low levels of CMV DNA. Histology of colonic resection showed widespread viral cytopathic inclusions consistent with CMV infection. Patient improved from her CMV disease with steady reduction of viral load but her recovery has been protracted due to other medical and surgical complications Conclusions: In the era of increasing biologics use, this case demonstrates the need for continued vigilance in patients treated with biologics. It is important to consider CMV colitis in patients with unexplained diarrhea and cytopenia on immunosuppression/biologics/ steroids especially with risk factors such as known previous/current IBD. Disclosures: The authors have declared no conflicts of interest. Background: Sjö gren's syndrome (SS) is an autoimmune disease characterized by high affinity circulating autoantibodies and peripheral B-cell disturbances with predominance of naïve and reduction of memory B cells. The stage at which errors in B-cell tolerance checkpoints accumulate in SS is unknown. Here we determined the frequency of self-and poly-reactive B cells in the circulating naïve compartment of SS patients. Methods: Single CD27-IgDþ B cells were sorted by FACS from peripheral blood of SS patients and healthy donors (HD). RNA was used to amplify Ig VH and VL genes and PCR products were cloned and expressed as recombinant monoclonal antibodies displaying identical specificity of the original B cells. Recombinant antibodies were tested towards different antigens to determine the frequency of autoreactive and polyreactive clones. Results: 66 recombinant antibodies were generated from naïve B cells of 4 SS patients and compared with 45 clones from 2 HD. Analysis of the VH and VL gene usage showed no significant differences between SS and HD. Conversely, we observed accumulation of circulating autoreactive naïve B cells in SS as demonstrated by increased reactivity towards Hep2 cells (43.1% SS vs 25% HD) and ENA (19.6% SS clones vs none). Among ENAþ clones, 6 displayed reactivity towards Ro/SSA and/or La/SSB. Conclusions: Here using an efficient strategy to express recombinant monoclonal antibodies from single B cells we demonstrated an elevated frequency of autoreactive naïve B cells in the circulation of SS patients supporting the existence of early defects in B-cell tolerance checkpoints in SS. Disclosures: The authors have declared no conflicts of interest. Background: Multiple studies and a systematic review suggest a steroid injection for tennis elbow improves many short-term (6 weeks) outcome measures including pain and thereby allow a quicker return to work. The aim of this study was to establish if an intramuscular (IM) steroid injection was as effective in the short term (6 weeks) for pain relief and functional disability as an intralesional (IL) steroid injection in tennis elbow. Secondly to establish if an IM steroid injection was less painful than an IL steroid injection at the point of delivery and for 48 h later. Methods: The study was a prospective, randomized controlled trial. 19 patients who had not had treatment for tennis elbow in the preceding 3 months were recruited from the investigators clinic. 9 patients were randomized to receive an 80 mg IM depomedrone injection into their gluteal muscle. 9 patients were randomized to receive a 40 mg depomedrone intralesional injection into the affected arm. 1 patient was withdrawn from the final analysis as their recruitment was deemed a protocol violation. The primary outcome measures were pain severity and functional disability as assessed by a Patient Rated Tennis Elbow Evaluation (PRTEE) Questionnaire and pain severity at the site of the injection as assessed by a 10 point Likert scale. The later was assessed, immediately after the injection, 24 h later and then 48 h later. The secondary outcome was complications of treatment. Results: Mean age in the IM arm was 45 years and IL arm was 43.5 years. 83% of patients had problems with their dominant arm. Six weeks after the treatment there were reduction in pain symptoms, improvement in function and total PRTEE scores in both IM and IL groups (P ¼ 0.008). A statistically significant result (P ¼ 0.001) in favour of IM causing less pain at the injection site was noted at the time of injection; however, statistical significance was not reached at 24 h (P ¼ 0.031) nor at 48 h (P ¼ 0.113). The IL Total PRTEE mean change was 43 points whilst IM Total PRTEE change was 38 points at 6 weeks. The difference between IL and IM therapy was -5 points in favour of IL therapy. This was less than the -10 points that was taken as the acceptable MCID. However the CI interval was large ranging from -26 points to þ16 points.
ACCUMULATION OF CIRCULATING AUTOREACTIVE NAÏVE B CELLS REVEALS DEFECTS OF EARLY B-CELL TOLERANCE CHECKPOINTS IN PATIENTS WITH SJÖ GREN'S SYNDROME
Elisa
Conclusions:
The results indicate that 6 weeks after both an IM and an IL steroid injection, pain, function and total PRTEE scores improved in both groups. The IM route caused significantly less pain at the site of injection at the time of injection. Both treatments were considered to be safe. This study did not however confirm non-inferiority of the IM over the IL procedure. Disclosures: The authors have declared no conflicts of interest. Background: Benign joint hypermobility syndrome (BJHS) is a connective tissue disorder which is characterized by excessive joint flexibility and subsequent musculoskeletal dysfunction including chronic pain. Psychological factors have an acknowledged contribution to pain. However, the pattern of psychological comorbidities in BJHS has not been well characterized. The aim of this study is to examine evidence linking BJHS with psychological factors through a systematic review of the literature and meta-analysis. Methods: Searches were conducted in AMED, CINAHL, MEDLINE, EMBASE, PubMed, Cochrane Library and in unpublished research databases (OpenGrey, the WHO International Clinical Trials Registry Platform, Current Controlled Trials, the UK National Research Register Archive) from their inception to October 2012. These included casecontrol and cohort studies which assessed the prevalence and incidence of psychological features in people diagnosed with BJHS. Meta-analysis was performed to assess odds ratio (OR) or prevalence and standardized mean difference in severity of psychological features. Methodological quality was assessed using a CASP appraisal tool. Results: Fourteen papers were identified as eligible. These included 3957 participants, 1006 people with BJHS and 2951 controls without BJHS. This evidence-base was found to be of moderate methodological quality. The results indicated that people with BJHS experience significantly more severe fear (P < 0.05) and are at greater risk of agoraphobia (P < 0.05), anxiety (OR: 4.39; 95% CI 1.92, 10.40), depression (OR: 4.10; 95% CI 1.79, 9.41) and panic disorders (OR: 6.72; 95% CI 2.22, 20.35 ) than those without BJHS (P 0.005) . People with BJHS demonstrate statistically significantly greater anxiety scores compared with those without BJHS (P < 0.001). No studies were identified which assessed psychological features in a childhood BJHS cohort. Conclusions: This is the first attempt to characterize the pattern of emotional symptoms experienced in BJHS through systematic review techniques. This demonstrates that a range of psychological morbidities are experienced. Whilst cause and effect cannot be established in these data, these observations point to possible approaches for managing BJHS through psychological and behavioural interventions. However, responses to various questions about referral and diagnostic work-up for patients with axSpA were generally similar in both practice settings. The majority of respondents (87%) reported that primary care providers referred patients with chronic back pain for 3 months and onset <45 years old; 47% of respondents received referrals from other specialists such as dermatologists, gastroenterologists, and ophthalmologists. Other than chronic and inflammatory back pain, referrals from non-rheumatology specialists were triggered by the occurrence of uveitis (82% of respondents), IBD (48%) and skin lesions (46%). At the time of referral to a rheumatologist, 48% reported that patients have symptoms for !3 years. The ASAS criteria were cited by 85% of respondents as the most common classification criteria that guide respondents in the diagnosis of axSpA in clinical practice, compared with the modified New York criteria for AS (23%), ESSG (8%), and Amor (6%). In terms of diagnostic work-up, approximately half systematically request HLA-B27 typing. MRI of the sacroiliac joints is Background: Significantly greater improvements in health-related quality of life (HRQoL) and reduction of impact of disease on work productivity were observed in patients with AS treated with golimumab (GLM) compared with placebo at weeks 14 and 24. We examined the association of ASDAS major improvement and inactive disease with these improvements and the maintenance over 2 years. Methods: In GO-RAISE, 356 patients with AS by the modified NY criteria were randomized (1.8:1.8:1) to SC GLM 50 or 100 mg or placebo q4w. HRQoL was assessed using the Physical Component Summary (PCS) and Mental Component Summary (MCS) of the SF-36. Self-reported employability data, defined as currently working or able to work if a job is available, were collected. Impact of disease on productivity in daily work, school or home was assessed using a visual analogue scale (0-10). ASDAS (using CRP) inactive disease was defined as a score <1.3 and major improvement was defined as an improvement from baseline !2. An ANOVA on van der Waerden Background: AS is a chronic inflammatory disorder, causing progressive pain and stiffness of the spine and peripheral joints. A systematic review of the literature revealed a high prevalence of possible depression (23-36%) and possible anxiety (45-57%) in patients with AS. However, few existing studies have focused on the relationships between mood and AS severity. The aim of this study was to explore the cross-sectional and prospective relationships of disease severity and mood disturbance in patients with AS. Methods: Participants in a multicentre UK cohort of AS patients, from 10 secondary care rheumatology centres across the UK, received baseline and 6 month follow up postal questionnaires. Disease severity measures were collected including: disease activity (BASDAI), pain (numerical rating scale) and function (BASFI). Mood was assessed by the Hospital Anxiety and Depression. Between baseline and 6-month follow up, Improvements/deteriorations in mood and disease severity were defined according to minimal clinically important differences. Results: 612/1000 AS patients responded at baseline and 470/612 at 6 months. The majority of baseline responders were male (72.2%), with a mean age of 50.80 (S.D. 12.22) years and mean symptom duration of 22.37 (S.D. 12.37) years. The baseline prevalence of possible depression and anxiety were 32% and 45%, respectively. Possible depression was associated with increased disease activity (OR 3.09, 95% CI 1.63, 5.86), pain (OR 2.65, 95% CI 1.38, 5.09) and functional impairment (OR 3.10, 95% CI 1.61, 5.97). Similarly, possible anxiety was associated with increased disease activity (OR 2.70, 95% CI 1.57, 4.65) and pain, (OR 2.61, 95% CI 1.50, 4.55) but less so with functional impairment (OR 1.96, 95% CI 1.12, 3.42) . Severity of mood disturbance at baseline was not associated with any significant change in disease activity, function or pain at 6 months. Similarly, severity of disease activity, function and pain at baseline was not associated with any significant change in anxiety or depression at 6 months. Conclusions: Patients with increased depression and/or anxiety had both greater disease activity and pain. However, depressive symptoms were more likely to occur in patients with functional restriction. Longer follow-up studies of more than 6 months may be required to investigate any causative inter-relationships between mood and disease severity. Disclosures: The authors have declared no conflicts of interest. (Table 1 ). Week24 PASI75 response for patients with !3% psoriasis body surface area at BL (61.6%) was 62.2% with CZP 200 mgq2W and 60.5% with 400 mgq4W vs 15.1% PBO (P < 0.001 for both). In patients with BL enthesitis (64.3% RS) LEI change from BL at week 24 was -2.0 with CZP 200 mgq2W (P < 0.001) and -1.8 with 400 mgq4W (P ¼ 0.003) vs -1.1 PBO. For patients with BL nail disease (73.3% RS) week 24 mNAPSI change from BL was -1.6 with CZP 200 mgq2W and -2.0 with 400 mgq4W vs -1.1 PBO. No differences in LDI change from BL were observed in patients with BL dactylitis. Week24 ACR response rates were similar between CZP arms, irrespective of prior anti-TNF exposure (Table 1) . Adverse events (AEs) occurred in 62% vs 68% and SAEs in 7% vs 4% in CZP (combined dose) vs PBO, respectively. Two deaths occurred up to week 24, one sudden death of unknown cause and one myocardial infarct. No new safety signals were observed. Conclusions: Rapid improvements in the signs/symptoms of PsA, as well as psoriasis skin manifestations and nail disease, were observed across both CZP dosing regimens. Similar ACR response rates with CZP were observed in patients with and without prior anti-TNF exposure. i164 Thursday 25 April 2013, 10.30-11.30 POSTER VIEWING III studies. We set out to assess the feasibility, reliability and sensitivity to change of four radiographic scoring methods in PsA in order to inform discussion on the optimal method for long term observational studies. Methods: The radiographs from fifty consecutive patients commenced on anti-tumour necrosis factor (anti-TNF) therapy for PsA were included. Hand and feet radiographs taken at anti-TNF commencement and 2 years prior were scored with all four methods. Two readers, WT and DJ scored all the radiographs. Ten sets of hand and feet radiographs were scored in random order to assess inter-rater reliability and then scored 1 month later to estimate intra-rater reliability. The remaining radiographs were then scored with the prior score and radiographs available to optimize sensitivity to change. Feasibility was estimated using the average time taken to score each method. Inter-and intra-rater reliability was assessed using intra-class correlation coefficients (ICC). Sensitivity to change was estimated using a Standardized Response Mean (SRM) and Smallest Detectable Difference (SDD).
THE RELATIONSHIP BETWEEN BENIGN JOINT HYPERMOBILITY SYNDROME AND PSYCHOLOGICAL FEATURES: A SYSTEMATIC REVIEW AND META-ANALYSIS
IS THERE SUB-CLINICAL JOINT DISEASE IN EARLY
Results: The mean interval between radiographs was 2.1 years. The patients' mean age was 54.7 years, mean disease duration 17.1 years.
Results are reported in Table 1 . The low inter-rater reliability for the STB (0.34) was related to disagreement on the presence of osteopenia in 3 of 10 cases. All 50 baseline radiographs were therefore scored using the STB by both readers to better reflect the frequency of osteopenia and hence better estimate the performance of the STB (ICC 0.84). Intra-rater reliability was excellent for all methods (ICC >0.98).
Conclusions:
The scores' reliability and sensitivity to change are consistent with reports in RA. The MSS and VDH scores were the most reliable and sensitive to change but took longer to perform. The SDD of the RAT is close to that of the VDH and MSS but is quicker to perform and through inclusion of proliferation may be more specific to PsA. The choice of method may vary depending upon individual study requirements. Background: It is increasingly recognized that factors related to skeletal biomechanics may play a key role in the pathogenesis of AS and related SpA. Physiotherapy and regular exercise are advocated in the management of AS, being beneficial for the management of pain, fatigue and depression in AS. Physical activity and mechanical injury have also been linked to joint inflammation in PsA. This study aimed to explore patient perception of the effect of physiotherapy on AS, the effect of AS on sport participation, and to assess the prevalence of recalled injury and its temporal association with AS onset. Methods: An online questionnaire was devised and disseminated electronically to members of the National Ankylosing Spondylitis Society (NASS). Results: A total of 1026 responses were received. The majority of respondents (61.4%, n ¼ 630) classed themselves as having been either 'very active' or 'quite active' participants in sport prior to diagnosis with AS. A third (28.5%, n ¼ 292) reported that they had to give up a sport completely after diagnosis. A further 228 (22.2%) had otherwise reduced participation in sport, and 244 (23.8%) switched to a less strenuous sporting activity. 284 respondents (27.7%) reported that the recommended physiotherapy exercises led to a flare of their symptoms. 332 (32.4%) reported modification of their recommended exercises to lessen disease flares. 452 (44.1%) respondents recalled an instance of trauma prior to the onset of AS that they felt had triggered their disease; 30% reported some instance of trauma weeks or days before onset and 70% recalled trauma months or years before onset of back pain. Conclusions: Individuals with AS report decreased participation in sport following disease diagnosis. This has implications for overall health and well-being beyond their AS. A number of patients reported that disease flare may have been precipitated by exercise recommended for their AS. A significant proportion of respondents recalled physical trauma prior to onset of symptoms, suggesting that patients may attribute disease to trauma. Several epidemiological studies support such a hypothesis in SpA. However, this patient survey is susceptible to responder and recall bias. These findings suggest that exercise and sport, though shown to be of benefit in AS, may paradoxically be a factor in symptom flare. Further longitudinal studies and inception cohorts are necessary to explore these issues in detail. Disclosures: The authors have declared no conflicts of interest. Background: Work disability (WD) is an important outcome measure in SpA. WD in SpA is high and may be associated with disease activity, comorbidities, depression and socioeconomic factors. The Work Productivity and Activity index has been validated in AS using data from randomized controlled trials and termed the WPAI-SpA. No data exist on the performance of the WPAI-SpA in the wider SpA population. We set out to assess the feasibility, construct validity and discrimination of the WPAI-SPA in a real world cohort of patients with SpA. Methods: Patients were selected from the Royal National Hospital for Rheumatic Diseases SpA database. All patients have a physician diagnosis of SpA. Data are collected at routine clinical follow up and the WPAI-SpA has been collected since August 2010. All patients who had completed a WPAI-SpA were eligible for inclusion. Data from the most recent assessment were analysed in this cross sectional study. Correlations with other measures were explored using spearman correlation coefficients to measure construct validity. The MannWhitney U was used to measure the difference in WPAI-SpA between high and low disease activity as a measure of discrimination. Results: 493 patients were included in the study, the patients' mean age was 51 years, mean disease duration was 19 years. 345 were of working age, 282 (79%) were employed. A further 9 patients were >65 and in employment and were included in the analysis. Of the 291 in employment 192 had AS, 99 with psoriatic, enteropathic, reactive, juvenile, axial or undifferentiated SpA. 207 (71%) were HLAB27 positive. The mean BASDAI was 3.6 S.D. (2.22) , BASFI 3.0 (2.25), Spinal VAS 3.5 (2.62), Global VAS 3.69 (2.65). Absenteeism, presenteeism, work productivity loss and activity impairment over the last week were 2.3%, 28.5%, 30.0% and 42.4% respectively. The WPAI-SpA was found to be inexpensive and easy to administer in the clinic setting. Correlations and discrimination between high and low activity are reported in Table 1 . The WPAI was able to distinguish between high and low disease activity (defined by the median Global VAS of 3.0) in presenteeism, productivity loss and activity impairment. Conclusions: The WPAI-SpA domains of presenteeism, productivity loss and activity impairment correlated well with other patient reported outcomes and discriminated between high and low disease activity providing initial evidence for its use in SpA. The low levels of absenteeism in our cohort may account for the lack of correlation with other measures. Background: Inflammatory back pain (IBP) is a characteristic feature of SpAs. Our service provides a model and screening pathway to assist others setting up early inflammatory back pain services. Several factors contribute to long delays in diagnosis of AS, deferring specialist referral until irreversible structural damage has occurred [1] . Early assessment and diagnosis is fundamental to provide effective treatment and prevent physical, emotional and socioeconomic consequences [2] .
CROSS-SECTIONAL
Objectives: (i) To develop an Early Inflammatory Back Pain Service (EIBPS) pathway, and (ii) to implement an educational campaign focused on early diagnosis of IBP raising awareness to GPs, allied healthcare practitioners (AHPs) and secondary care colleagues. Methods: Patients with suspected IBP were screened in the EIBPS referred from primary and secondary care. Each was assessed for IBP (Berlin criteria) and other SpA features. Bloods including HLA-B27 were taken for those with IBP or suspected axial SpA. X-ray of SIJs and/or MRI taken (if sacroiliitis not evident on plain film). An educational campaign was undertaken-circulating posters to local community areas, writing local newspaper leads and formal education on IBP for GPs, AHPs and secondary care colleagues. Results: 137 patients with suspected IBP were screened in the EIBPS over 24 months (Table 1 Background: There is convincing evidence for an association between RA and chronic periodontitis (PD). However, there is a lack of evidence regarding an association between PD and other rheumatic diseases. Recently, a large study has suggested an association between AS and PD, supporting three earlier smaller studies in different populations.
The oral cavity represents the second largest reservoir of commensal micro-organisms in the human body after the intestinal tract. Evidence suggests that microbial dybiosis plays a role in the initiation and perpetuation of AS. Identification of oral pathology and an association with disease activity would suggest that this process may begin in the mouth. As yet, no studies have investigated a potential association between disease activity in AS and PD, although such an association has been reported in RA.
The aim of this study was to compare the prevalence of periodontal disease in patients with AS, to assess their oral health status, disease activity and oral health related quality of life and to compare this with healthy controls.
i166 Thursday 25 April 2013, 10.30-11.30 POSTER VIEWING III Methods: Forty-one patients with AS fulfilling the modified New York criteria and 49 healthy controls individually matched for age, sex and ethnicity (mean age 42.5 years; S.D. 13.7) participated in this casecontrol study. Data collection included probing pocket depth, clinical attachment loss (CAL), bleeding on probing (BOP), plaque index, oral mucosal conditions, caries status and salivary flow rate (SFR). Sociodemographic characteristics, medical history and oral-health-related quality of life (OHRQoL) were measured using the OHIP-14 questionnaire. Disease activity in AS patients was assessed using the BASDAI. Results: AS Patients had a higher prevalence of periodontitis (!2 sites with CAL of !4 mm) than the healthy controls (87.8% vs 71.4%; P ¼ 0.06). A positive gradient was observed between BASDAI DAS in AS and periodontal disease severity. The mean plaque score and the extent of BOP were significantly higher in cases than controls (P < 0.05). The other oral health characteristics and the mean SFR were similar in both groups. Mean OHIP-14 scores were higher in cases than controls (P < 0.05). Two patients developed lupus-like or vasculitic symptoms: i) after 15 months INF monotherapy a male (age 52, disease duration 24 years) developed nail fold infarcts, ulnar mononeuritis, positive ANA, dsDNA, and non-specific ANCA. Symptoms resolved with 3 pulses of cyclophosphamide and i.v. methylprednisolone. ii) after 44 months INF and MTX a female with psoriatic spondylitis (age 43, disease duration 5 years) became ANA positive in a speckled pattern later changing to PCNA: highly specific for SLE. Two years later she developed a malar rash, photosensitivity, hair loss, and mouth ulcers. ANCA, dsDNA and complement remained normal. Symptoms resolved within 6 months following steroids and HCQ. Treatment was not altered in either case prior to the development of new symptoms despite seroconversion and close monitoring. ANA reverted to negative after discontinuation of INF. Conclusions: ANA seroconversion is common in AS patients treated with INF and remains persistent during drug exposure. Although ANA seroconversion was widespread, development of new symptoms was rare and resolved after withdrawal of INF. This questions the value of such frequent ANA monitoring in the absence of additional symptoms.
(ASAS criteria)/early AS. Further we asked rheumatologists to provide an estimate of their confidence in prescribing these drugs in axSpA/ early AS if this was supported by NICE; and by how much this would increase their prescribing. Methods: An electronic survey consisting of 10 questions was designed using Survey Monkey and e-mailed to 177 named UK based rheumatologists representing all acute NHS Trusts. The questionnaire was re-sent to non-responders 2 weeks later. Results: Twenty-five per cent of rheumatologists contacted (41/165) completed the survey. Immediate returns were received for 12 e-mail addresses either with out of office replies (n ¼ 2) or delivery failures (n ¼ 10). Estimated numbers of AS patients attending per unit varies considerably between hospitals from <50 (15% of participants) to >500 patients (10%). A quarter of centres (24.4%) have an estimated 100-200 AS patients under follow-up. More than 60% of AS patients seen across rheumatology centres in the UK have established disease fulfilling the mNYC. The estimated number of axSpA patients seen varies from <20% (35% of the centres) to 20-50% (40% of centres). An estimated 40% of AS patients attending secondary and tertiary care in the UK currently receive treatment with a TNFi. By contrast <10% of axSpA/early AS are being treated with a TNFi. Eighty-eight per cent of rheumatologists have no dedicated commissioning pathway to allow for this prescription. 68.3% of respondents would be confident in prescribing TNFi for axSpA if this were approved by NICE, and would like to be able to prescribe independently of whether the diagnosis was made according to the imaging or the clinical arm of the ASAS criteria. Importantly 60% of rheumatologists felt that their overall prescription would increase by <25% if TNFi could be prescribed in axSpA. Conclusions: UK rheumatologists appear largely compliant with NICE guidance on TNFi in AS. However they would like to treat AS patients earlier and this would only represent a minimum increase over current numbers. These data are crucial for health-economic calculations in anticipation of a positive statement by NICE. Background: There is an unacceptable delay to rheumatology referral for patients with SpA. Previous work has considered screening for SpA in clinics for associated conditions e.g. psoriasis. A specific form of HLA B27 associated acute anterior uveitis (AAU) is the most common extrasynovial manifestation of SpA and presents primarily to eye casualty departments. Service review elsewhere [1] showed that referral from ophthalmology was infrequent but had a high yield. We aimed to review the feasibility and likely yield of screening for SpA in patients presenting to eye casualty with this type of AAU. Methods: We devised and piloted a screening questionnaire based on the work of Rudwaleit [2] to elicit symptoms of SpA and presence of related conditions. After an educational programme including training and posters, the tool was used by eye casualty staff for consecutive patients presenting with AAU over 3 months. Hospital electronic records were used to confirm their ocular diagnosis. Results: 118 questionnaires were completed in 92 days. 25 (21%) responses were deemed invalid; 17 had the wrong type of uveitis, others mainly for inadequate completion. Of the remaining 93, 24 were already known to have AS and 12 had other relevant conditions. 5 had psoriasis and 7 had IBD (5 Crohn's disease, 2 ulcerative colitis). For those not already known to have SpA (n ¼ 69) the frequency of positive responses to the questionnaire are shown below:
(i) Reported features by patients with AAU, excluding AS patients (n ¼ 69) (ii) Known comorbidities: psoriasis 5 (7%); Crohn's 5 (7%); ulcerative colitis 2 (3%) (iii) Family history: psoriasis 8 (12%); AS 5 (7%); Crohn's 6 (9%); ulcerative colitis 1 (1%)
Reported symptoms: back pain 34 (49%); radiation of pain to buttocks 19 (28%); sleep disturbance due to back pain 15 (22%); back stiffness 10 (14%); joint swelling 18 (26%) Conclusions: HLA B27 related AAU presents commonly to eye casualty departments. Our results suggest that a high proportion of such patients have symptoms which might indicate an undiagnosed SpA. Further work is needed to determine the specificity of such symptoms. Our work shows that the correct type of AAU is not universally recognized in eye casualty departments by non-specialist staff and so review in specialist uveitis or medical ophthalmology clinics may be required. These results suggest however that targeted screening of those presenting with HLA B27 type AAU may identify a significant number of patients likely to have SpA, thereby reducing their referral delay to rheumatology and increasing the rate of prompt appropriate treatment. Disclosures: L.K., Roche-Advisory Board, Pfizer-Speaker Fees. All other authors have declared no conflicts of interest.
BASDAI CREEP: CHANGING PERCEPTIONS OF SYMPTOMS DESPITE SUSTAINED TREATMENT EFFICACY?
Iona Thorne Background: The BASDAI is the most widely used measure of disease activity in AS and is a critical measure for assessing outcomes of treatment in AS. It relies on patients' subjective appreciation of their symptoms. Patients' perceptions of symptoms severe may vary over time irrespective of the efficacy of treatment. Other scoring systems, including measures of function, metrology, quality of life and inflammation are therefore important elements of assessments of disease activity. After observing variation in BASDAI measures in patients otherwise apparently continuing to respond well to TNF inhibitor (TNFi) treatment we reviewed sequential changes in BASDAI and visual analogue scale spinal pain (VAS SP) scores in patients on long-term TNFi in relation to other parameters of disease activity. Methods: A retrospective review of our local AS database was conducted. All patients who had received TNFi medication for over 250 weeks for whom complete datasets were available were included in the study. Patients who had switched biologic treatments were also included. BASDAI, BASFI, ASQOL and BASMI scores were recorded, as were ESR and CRP where available. All patients met modified New York Criteria for diagnosis of AS and eligibility for and response to TNFi treatment were as defined by NICE. Results: Data were collected for 26 patients (5 female) with AS. Mean duration of treatment was 370 (range 254-488) weeks. 9 were taking Adalimumab, 12 etanercept and 8 infliximab. 3 patients had switched to a second TNFi. The mean BASDAI score pre-treatment was 6.48 (range 4.16-9.35); this fell by a mean of 4.0 units at 8-16 weeks of treatment. The mean time to optimal (nadir) BASDAI response was 193 weeks (range 6 -373), and mean time to nadir VAS SP scores was 113 weeks (range 6-320). During the subsequent period of observation, BASDAI and/or VAS SP rose to NICE treatment failure levels on three or more consecutive visits in five patients and in a further six patients BASDAI and/or VAS SP measures rose over three or more consecutive visits. No corresponding changes in acute phase response were seen. Treatment continued in all 11 patients and all reported a sustained symptomatic response. Conclusions: Tendency of symptomatic clinical measures to revert to the mean is well recognized. This phenomenon, referred to by us as BASDAI creep, appears to be a significant phenomenon in AS. This is likely to be multifactorial. In some this may reflect changing perception of current symptoms relative to baseline levels. In 5 patients treatment was continued despite failing to meet criteria for ongoing therapy on the basis of continued evident wellbeing and patient choice. If this reflects the reality of long-term treatment of AS the case for adopting more objective measures, such as the ASDAS, is compelling. Disclosures: The authors have declared no conflicts of interest. Background: Chronic inflammation in AS is associated with vascular endothelial dysfunction which leads to accelerated atherosclerosis. Accelerated atherosclerosis probably contributes to the increased cardiovascular mortality in AS. The aim of this study was to determine the effect of spironolactone on endothelial dysfunction in anti-TNF naive AS patients. Methods: 20 anti-TNF naive AS patients (M/F ¼ 15/5) with high disease activity (BASDAI >4) despite treatment with stable doses of conventional DMARDs were investigated. Inflammatory disease activity (BASDAI and BASFI, ESR and CRP levels); serum nitrite concentration, and endothelium-dependent and independent vasodilation of the brachial artery were measured at baseline and after 12 weeks of therapy with oral spironolactone 2 mg/kg/day. Ten healthy subjects matched for age and sex acted as the control. Results: FMD in AS patients at baseline was significantly impaired as compared with a healthy control group (P < 0.001). After treatment: FMD improved from 11.3 AE 1.70 to 24.69 AE 2.34% (P < 0.001), nitrite concentration reduced from 7.9 AE 0.28 to 4.79 AE 0.19 mmol/l, P < 0.001), ESR from 33.8 AE 4.38 to 15.13 AE 1.30 mm in Ist hr, (P < 0.001) and CRP level from 22.39 AE 3.80 to 6.3 AE 1.29 mg/dl, (P < 0.001). BASDAI and BASFI reduced significantly (P < 0.001).
SPIRONOLACTONE IMPROVES ENDOTHELIAL DYSFUNCTION IN ANKYLOSING SPONDYLITIS
Conclusions:
The study suggests that in AS endothelial dysfunction is a part of the disease process. This is the first study to show that treatment with spironolactone improves both endothelial dysfunction and inflammatory disease activity in AS. Disclosures: The authors have declared no conflicts of interest. Background: Early diagnosis is the key to the successful management of axial spondylarthritis (SpA). Unfortunately, there is a well recognized delay: the most recent study by Feldtkellar et al (2003) reported an average time to diagnosis of 10 years. Within the military, a specific back pain pathway has been implemented promoting recognition of SpA and early referral to DMRC Headley Court, a specialist centre for the diagnosis and management of SpA. We believe that the time to diagnosis in axial SpA is shorter within the military compared with the general population and devised this study to test the hypothesis. Methods: Service personnel attending the Axial SpA Inpatient Rehabilitation and Education (ASPIRE) course at DMRC Headley Court from March 2010 to November 2012 were identified. Information regarding age, time to diagnosis, radiological findings and the health care professional who confirmed the diagnosis was retrieved from medical records. In those cases where time to diagnosis was not clear, patients were contacted directly. Results: Results from 132 patients were retrieved. The mean age of patients was 35.2 years with a male to female ratio of 10:1. 73.5% of patients had a diagnosis of AS, 20.5% undifferentiated axial SpA and 5.3% psoriatic spondylarthritis. The majority of patients received their diagnosis from a consultant (87.1%) and the most common methods of imaging were MRI (78.0%) and X-ray (60.6%). The mean time to diagnosis for all patients was 5.7 years, (range 0-25) from symptom onset. The difference in time to diagnosis between the sexes was marked with SpA being diagnosed on average 3 years later in women. There was no difference in time to diagnosis between patients with AS and axial SpA. Diagnosis was made in 10 years or less in 80.0% of the patients Conclusions: Patients in the military are diagnosed with axial SpA on average 4.3 years earlier when compared with an average 10 year delay in the general population. 80% of military personnel who attended rehabilitation at DMRC Headley received a diagnosis of axial SpA within this 10 year average. This reflects the increased awareness of military primary care doctors and physiotherapists, the accessibility of radiology resources and a clearly defined care pathway which encourages early specialist intervention. Disclosures: The authors have declared no conflicts of interest. LTFU (n ¼ 270). Data are shown as n (% of 270). *P < 0.05; **P < 0.01; ***P < 0.001. Department of Medicine, Imperial College London, London, UK Background: There are limited data available on the outcomes of pregnancy in women with anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV). Previous publications describe frequent complications including first trimester miscarriages, pre-term birth, premature rupture of membranes and disease relapse resulting in fetal and maternal death. Many of these studies are old and based on isolated case reports. The objective of the current study was to describe recent pregnancy outcomes in women with AAV. Methods: Retrospective case analysis of all women who became pregnant following a diagnosis of ANCA associated vasculitis in the cohort of patients treated in 3 UK centres. Results: 10 pregnancies were observed in 8 patients following a diagnosis AAV (granulomatosis with polyangiitis n ¼ 7, microscopic polyangiitis n ¼ 1). All patients were in clinical remission with low or undetectable serum ANCA titres at the time of conception and had no other risk factors for antenatal complications. Methotrexate was discontinued in all patients with a planned pregnancy. Seven patients were managed with AZA in combination with prednisolone one patient was managed with prednisolone alone. One patient had a first trimester miscarriage following an unplanned pregnancy whilst taking MTX. One patient experienced a second trimester disease relapse which was treated successfully with immunoglobulin G and plasmapheresis and progressed with an otherwise uncomplicated pregnancy. Nine live births were observed with all infants born at full term by normal vaginal delivery with the exception of one patient with twin pregnancy and one patient with breech presentation who underwent an elective Caesarean section. There were no obstetric or neonatal complications and no disease relapse reported in the post-partum period. Conclusions: Planned pregnancy during remission in ANCA associated vasculitis is safe with a low incidence of fetal and maternal complications. Patients should be on appropriate immunosuppression at conception. Disease relapse can be treated successfully without causing fetal complications. Disclosures: The authors have declared no conflicts of interest.
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